{\rtf1 \ansi 
{\colortbl;
\red0\green0\blue0;
\red255\green255\blue255;
\red255\green0\blue0;
\red0\green255\blue0;
\red0\green0\blue255;
\red0\green255\blue255;
\red255\green0\blue255;
\red255\green255\blue0;
\red0\green0\blue128;
\red0\green128\blue128;
\red0\green128\blue0;
\red128\green0\blue128;
\red128\green0\blue0;
\red128\green128\blue0;
\red128\green128\blue128;
\red192\green192\blue192;
\red170\green170\blue170;
\red85\green85\blue85;
\red80\green80\blue80;
\red51\green51\blue51;
\red37\green37\blue37;
\red254\green254\blue0;
\red14\green86\blue140;
\red56\green124\blue43;
\red119\green119\blue119;
\red204\green204\blue204;
\red151\green151\blue151;
\red246\green246\blue246;
\red21\green137\blue21;
\red247\green247\blue247;
\red33\green33\blue33;
\red255\green255\blue102;
\red255\green255\blue174;
\red106\green144\blue39;
\red239\green122\blue2;
\red107\green107\blue106;
\red240\green240\blue240;
\red20\green93\blue164;
\red105\green105\blue105;
\red236\green236\blue236;
\red187\green187\blue187;
\red181\green79\blue104;
\red255\green248\blue96;
\red232\green233\blue232;
\red118\green118\blue118;
\red233\green233\blue233;
\red0\green114\blue54;
\red249\green249\blue249;
\red112\green112\blue112;
\red251\green252\blue255;
\red72\green72\blue72;
\red190\green195\blue204;
\red188\green41\blue30;
\red190\green237\blue228;
\red61\green61\blue61;
\red223\green223\blue223;
\red239\green239\blue239;
\red204\green255\blue255;
\red255\green255\blue198;
\red227\green227\blue227;
\red190\green190\blue252;
\red238\green238\blue238;
\red214\green9\blue9;
\red185\green185\blue185;
\red218\green218\blue218;
\red214\green214\blue214;
\red153\green153\blue153;
\red71\green120\blue194;
\red255\green255\blue204;
\red255\green204\blue0;
}
{\fonttbl {
\f0 Arial;}{
\f1 Symbol;}{
\f2 Times New Roman;}{
\f3 sans-serif;}{
\f4 georgia;}{
\f5 serif;}
}
{\*\generator Apache XML Graphics RTF Library;}
\fet0 \ftnbj \paperw12240 \paperh15840 \margt1080 \margb1080 \margl1080 \margr1080 \headery720 \footery720 \itap0 \cols2 
\sectd {\header {
{\trowd \ltrrow \trleft0 
\clpadb60 \clpadfb3 \clpadl400 \clpadfl3 \clbrdrt \clbrdrb \brdrcf17 \brdrw20 \brdrs \clbrdrl \trql \clvertalb \clwWidth9380 \cellx9380 
\clpadb60 \clpadfb3 \clpadl400 \clpadfl3 \clbrdrt \clbrdrb \brdrcf17 \brdrw20 \brdrs \clbrdrr \trql \clwWidth700 \cellx10080 
\intbl 
{\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 
}
{\b1 \cf18 \f0 \i0 \fs18 
{\b1 \cf18 \f0 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Vanda Pharmaceuticals Inc. v. Roxane Laboratories, Inc., 203 F.Supp.3d 412 (2016)
}
}
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 
}
}\b0 \cf1 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs18 \li0 \sa0 \sb0 \intbl \cell \intbl 
{\qr \b0 \cf1 \f0 \ri0 \i0 \fs18 \li0 
}\qr \b0 \cf1 \f0 \ri0 \i0 \fs18 \li0 \intbl \cell \row }
{\trowd \lastrow \trleft0 
\clbrdrb \clbrdrl \trql \clwWidth10080 \cellx10080 
\intbl 
{\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 
}\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 \intbl \cell \row }}\par }{\footer {
{\trowd \lastrow \trleft0 
\clpadl60 \clpadfl3 \clbrdrt \brdrcf17 \brdrw20 \brdrs \clbrdrb \clbrdrl \trql \clvertalb \clwWidth9300 \cellx9300 
\clpadl60 \clpadfl3 \clbrdrt \brdrcf17 \brdrw20 \brdrs \clbrdrb \clbrdrr \trql \clwWidth700 \cellx10000 
\intbl 
{\b0 \cf17 \f0 \ri0 \i0 \ql \fs20 \li0 
{\b0 \cf17 \f0 \ul0 \strike0 \i0 \fs20 
}
{\*\shppict {\pict \pngblip \picw78 \pich10 \picwgoal1170 \pichgoal150 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}}
{\b0 \cf17 \f0 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u169\'3f 2021 Thomson Reuters. No claim to original U.S. Government Works.
}
}\b0 \cf17 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs20 \li0 \sa0 \sb0 \intbl \cell \intbl 
{\qr \b0 \cf17 \f0 \ri0 \i0 \fs20 \li0 
{\b0 \i0 \ul0 \fs20 \f0 \chpgn }
}\qr \b0 \cf17 \f0 \ri0 \ul0 \strike0 \i0 \fs20 \li0 \intbl \cell \row }}\par }
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_document_41}{\*\bkmkend co_document_41}
{\b0 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart I1391f6006c3811e69e6ceb9009bbadab_Target}{\*\bkmkend I1391f6006c3811e69e6ceb9009bbadab_Target}
\par 
}
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb100 
203 F.Supp.3d 412
\par 
}
}
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
United States District Court, D. Delaware.
\par 
}
}
}
{\b0 \qc \cf21 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \qc \cf21 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \qc \cf21 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \cf21 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
VANDA PHARMACEUTICALS INC. and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Search/Results.html?query=advanced%3a+OAID(5000067560)&saveJuris=False&contentType=BUSINESS-INVESTIGATOR&startIndex=1&contextData=(sc.Default)&categoryPageUrl=Home%2fCompanyInvestigator&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem" }{\fldrslt 
{\b0 \cf23 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
Aventisub LLC
}}}
{\b0 \cf21 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb240 
, Plaintiffs,
\par 
}
}
{\b0 \qc \cf21 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \cf21 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
v.
\par 
}
}
{\b0 \qc \cf21 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \cf21 \f4 \ul0 \strike0 \i0 \fs24 \sa240 \sb0 
ROXANE LABORATORIES, INC., Defendant.
\par 
}
}
}
}
{\b0 \qc \cf1 \f2 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Civil Action No. 13-1973-GMS, Civil Action No. 14-757-GMS
\par 
}
}
}
{\b0 \cf1 \f4 \i0 \fs20 
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
|
\par 
}
}
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa200 \sb0 
Signed August 25, 2016
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf31 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_synopsis_41}{\*\bkmkend co_synopsis_41}
{\b1 \cf31 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
Synopsis
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Background:
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Patent holder commenced actions against competitor that submitted paragraph IV certification in Abbreviated New Drug Application (ANDA), alleging infringement of patents on iloperidone and method for treating patient suffering from schizophrenia with iloperidone. Actions were consolidated. Bench trial was held. Parties submitted post-trial proposed findings of fact and post-trial briefs concerning validity of patents-in-suit and whether accused products infringed.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Holdings:
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The District Court, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0132747001&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Gregory M. Sleet
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
, J., held that:
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
ability of person ordinarily skilled in the art to easily modify butyrophenone compound by replacing its benzoyl moiety with benzisoxazole moiety did not mean that patent on iloperidone was obvious;
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
method for treating patient suffering from schizophrenia with iloperidone through use of genotyping assay and adjusting dose of iloperidone based on those results was not obvious due to level of clinical testing required and inherent unpredictability in that field;
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
method patent was directed toward a patent eligible subject;
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
data disclosing trend for higher prolongation in measurement of time in heart\rquote s electrical cycle among genotypic poor metabolizers of particular enzyme given 24 mg daily dose of iloperidone was sufficient to support possession of claimed dosage range for method patent, even if not statistically significant, and thus written description was satisfied;
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
competitor\rquote s submission of paragraph IV certification for iloperidone was act of infringement of method patent;
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
existence of substantial non-infringing use did not preclude finding of inducement to infringe patent;
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
accused product did not contribute to direct infringement of method patent; and
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
holder was entitled to permanent injunction against competitor to prevent it from infringing patent on method.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Ordered accordingly.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b1 \cf31 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_attorneysAndLawFirms_41}{\*\bkmkend co_attorneysAndLawFirms_41}
{\b1 \cf31 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
Attorneys and Law Firms
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_417_41}{\*\bkmkend co_pp_sp_7903_417_41}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*417
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0195687701&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Jack B. Blumenfeld
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0164817201&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Karen Jacobs
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Morris, Nichols, Arsht & Tunnell LLP, Wilmington, DE, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0330769501&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Eric A. Stone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0426581101&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Josephine Young
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0384392301&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Kira A. Davis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0142351601&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Nicholas Groombridge
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Pro Hac Vice, for Plaintiffs.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0221605201&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Richard L. Horwitz
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0438085701&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Bindu Ann George Palapura
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0322332601&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
David Ellis Moore
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Potter Anderson & Corroon, LLP, Wilmington, DE, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0431095001&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Emily C. Melvin
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0108551301&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Kenneth G. Schuler
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0447633601&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Michael R. Seringhaus
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, Timothy J. O\rquote Brien, Pro Hac Vice, for Defendant.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf31 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_opinion_41}{\*\bkmkend co_opinion_41}
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ifdddd5d21a0311ebb27dc1895c097}{\*\bkmkend co_anchor_Ifdddd5d21a0311ebb27dc1895c097}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ife1846c11a0311ebb27dc1895c097}{\*\bkmkend co_anchor_Ife1846c11a0311ebb27dc1895c097}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ife1846c11a0311ebb27dc1895c097}{\*\bkmkend co_anchor_Ife1846c11a0311ebb27dc1895c097}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa200 \sb800 
MEMORANDUM
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0132747001&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
GREGORY M. SLEET
}}}
\sa200 
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
, UNITED STATES DISTRICT JUDGE
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ife18e3021a0311ebb27dc1895c097}{\*\bkmkend co_anchor_Ife18e3021a0311ebb27dc1895c097}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ife18e3021a0311ebb27dc1895c097}{\*\bkmkend co_anchor_Ife18e3021a0311ebb27dc1895c097}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
I. INTRODUCTION
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In this consolidated patent infringement action, plaintiffs Vanda Pharmaceuticals Inc. (\u8220\'3fVanda\u8221\'3f) and Aventisub LLC (\u8220\'3fAventisub\u8221\'3f) (collectively \u8220\'3fthe Plaintiffs\u8221\'3f) allege infringement by Roxane of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2009579817&pubNum=0004073&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Id04ab71917f711db9a6ba61a2ffc7828&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Reissue Patent No. 39,198 (\u8220\'3fthe \lquote 198 Patent\u8221\'3f)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 8,586,610 (\u8220\'3fthe \lquote 610 Patent\u8221\'3f)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The two actions were consolidated for purposes of trial on April 13, 2015. The court held a five-day bench trial in this matter on February 29, 2016 to March 4, 2016. (D.I. 171\u8211\'3f176.) Presently before the court are the parties\rquote  post-trial proposed findings of fact and post-trial briefs concerning the validity of the patents-in-suit and whether Roxane\rquote s proposed products infringe the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. (D.I. 178, 179, 184, 185.)
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Pursuant to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR52&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Federal Rule of Civil Procedure 52(a)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and after having considered the entire record in this case and the applicable law, the court concludes that: (1) all asserted claims of the patents-in-suit are valid; (2) Roxane\rquote s proposed products induce infringement of the asserted claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; (3) Roxane\rquote s proposed products do not contributorily infringe the asserted claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; and (4) each of the parties\rquote  
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR52&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Rule 52(c)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 motions are 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_418_41}{\*\bkmkend co_pp_sp_7903_418_41}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*418
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 granted in part and denied in part. These findings of fact and conclusions of law are set forth in further detail below.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00012039653953_ID0EGGBI_41}{\*\bkmkend co_fnRef_B00012039653953_ID0EGGBI_41}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00012039653953_41" }{\fldrslt 
{\super \b0 \cf23 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
1
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ife1cb3911a0311ebb27dc1895c097}{\*\bkmkend co_anchor_Ife1cb3911a0311ebb27dc1895c097}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ife1cb3911a0311ebb27dc1895c097}{\*\bkmkend co_anchor_Ife1cb3911a0311ebb27dc1895c097}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
II. FINDINGS OF FACT
}
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00022039653953_ID0ESHBI_41}{\*\bkmkend co_fnRef_B00022039653953_ID0ESHBI_41}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00022039653953_41" }{\fldrslt 
{\super \b0 \cf23 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
2
}}}
\sb200 
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ife1e88501a0311ebb27dc1895c097}{\*\bkmkend co_anchor_Ife1e88501a0311ebb27dc1895c097}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ife1e88501a0311ebb27dc1895c097}{\*\bkmkend co_anchor_Ife1e88501a0311ebb27dc1895c097}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
A. The Parties
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
1. Plaintiff Vanda is a Delaware corporation with its principal place of business at 2200 Pennsylvania Ave NW, Washington, DC 20037.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
2. Plaintiff Aventisub is a Delaware corporation with its principal place of business at 3711 Kennett Pike, Suite 200, Greenville, DE 19807.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
3. Defendant Roxane is a Nevada corporation with its principal place of business at 1809 Wilson Road, Columbus, OH 43228.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
4. The court has subject matter jurisdiction as well as personal jurisdiction over all parties.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ife1fe7e11a0311ebb27dc1895c097}{\*\bkmkend co_anchor_Ife1fe7e11a0311ebb27dc1895c097}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ife1fe7e11a0311ebb27dc1895c097}{\*\bkmkend co_anchor_Ife1fe7e11a0311ebb27dc1895c097}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
B. Background
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
5. Genotyping assays are currently commercially available to identify CYP2D6 poor metabolizers.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
6. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ib3510dc6475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Genotyping
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 assays are laboratory tests.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
7. The generic iloperidone described in the Roxane AND A is literally within the scope of claim 3 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2009579817&pubNum=0004073&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Id04ab71917f711db9a6ba61a2ffc7828&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 198 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and infringes claim 3 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2009579817&pubNum=0004073&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Id04ab71917f711db9a6ba61a2ffc7828&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 198 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 provided that the claim is not proved invalid.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
8. Extrapyramidal side effects (\u8220\'3fEPS\u8221\'3f) are undesired side effects of antipsychotic medications.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
9. Atypical antipsychotics have fewer extrapyramidal side effects than typical antipsychotics.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ife21e3b11a0311ebb27dc1895c097}{\*\bkmkend co_anchor_Ife21e3b11a0311ebb27dc1895c097}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ife21e3b11a0311ebb27dc1895c097}{\*\bkmkend co_anchor_Ife21e3b11a0311ebb27dc1895c097}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
C. The Patents-in-Suit
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
10. The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2009579817&pubNum=0004073&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Id04ab71917f711db9a6ba61a2ffc7828&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 198 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, entitled \u8220\'3fHeteroarylpiperidines, Pyrrolidines and Piperazines and Their Use as Antipsychotics and Analgesics,\u8221\'3f issued on July 18, 2006, and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic9d53668475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
names
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 Joseph T. Strupczewski, Grover C. Helsley, Yulin Chiang, Kenneth J. Bordeau, and Edward J. Glamkowski as the inventors.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
11. The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2009579817&pubNum=0004073&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Id04ab71917f711db9a6ba61a2ffc7828&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 198 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 was filed on November 15, 2000, and is a reissued patent of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1994364898&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I957838a0746211d79c33f30f55d9158b&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. patent no. 5,364,866
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, filed on October 30, 1992.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
12. The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2009579817&pubNum=0004073&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Id04ab71917f711db9a6ba61a2ffc7828&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 198 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 claims priority to U.S. Patent Application No. 07/354,411, filed on May 19, 1989.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
13. The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2009579817&pubNum=0004073&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Id04ab71917f711db9a6ba61a2ffc7828&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 198 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 expires on November 15, 2016.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
14. Aventisub is the owner by assignment of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2009579817&pubNum=0004073&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Id04ab71917f711db9a6ba61a2ffc7828&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 198 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
15. Vanda holds an exclusive worldwide license to the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2009579817&pubNum=0004073&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Id04ab71917f711db9a6ba61a2ffc7828&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 198 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
16. The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, entitled \u8220\'3fMethods for the Administration of Iloperidone,\u8221\'3f issued on November 19, 2013, and names Curt D. Wolfgang and Mihael H. Polymeropoulos as the inventors.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
17. The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 claims priority to U.S. Provisional Application No. 60/614,798, filed on September 30, 2004.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_419_41}{\*\bkmkend co_pp_sp_7903_419_41}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*419
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 18. The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 expires on November 2, 2027.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
19. Vanda is the owner by assignment of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
20. Vanda has standing to sue for infringement of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ife2602611a0311ebb27dc1895c097}{\*\bkmkend co_anchor_Ife2602611a0311ebb27dc1895c097}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
1. 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa200 \sb400 
The Asserted Claims
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
a. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2009579817&pubNum=0004073&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Id04ab71917f711db9a6ba61a2ffc7828&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
\rquote 198 Patent
}}}
\sa200 
\sb400 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa200 \sb400 
, Claim 3
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Claim 3 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2009579817&pubNum=0004073&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Id04ab71917f711db9a6ba61a2ffc7828&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 198 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 reads:
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
A compound as claimed in claim 1, which is 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]-3-methoxyphenyl]ethanone or a pharmaceutically acceptable acid addition salt thereof. The nonproprietary name for l-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]-3-methoxyphenyl]ethanone is \u8220\'3filoperidone.\u8221\'3f
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ife2713d11a0311ebb27dc1895c097}{\*\bkmkend co_anchor_Ife2713d11a0311ebb27dc1895c097}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
b. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
\sa200 
\sb400 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa200 \sb400 
, Claims 1-9, 11-13, and 16
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Claims 1-9, 11-13, and 16 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 read:
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
A method for treating a patient with iloperidone, wherein the patient is suffering from 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ad584c475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
schizophrenia
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the method comprising the steps of: determining whether the patient is a CYP2D6 poor metabolizer by: obtaining or having obtained a biological sample from the patient; and performing or having performed a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ib3510dc6475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
genotyping
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 assay on the biological sample to determine if the patient has a CYP2D6 poor metabolizer genotype; and if the patient has a CYP2D6 poor metabolizer genotype, then internally administering iloperidone to the patient in an amount of 12 mg/day or less, and if the patient does not have a CYP2D6 poor metabolizer genotype, then internally administering iloperidone to the patient in an amount that is greater than 12 mg/day, up to 24 mg/day, wherein a risk of QTc prolongation for a patient having a CYP2D6 poor metabolizer genotype is lower following the internal administration of 12 mg/day or less than it would be if the iloperidone were administered in an amount of greater than 12 mg/day, up to 24 mg/day.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
2. The method of claim 1, wherein the performing or having performed the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ib3510dc6475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
genotyping
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 assay step comprises: extracting or having extracted genomic DNA or mRNA from the biological sample, and sequencing or having sequenced CYP2D6 DNA derived from the extracted genomic DNA or from the extracted mRNA, wherein the sequencing or having sequenced step further comprises: amplifying or having amplified a CYP2D6 region in the extracted genomic B-2 DNA or mRNA to prepare a DNA sample enriched in DNA from the CYP2D6 gene region; and sequencing or having sequenced the DNA sample by hybridizing the DNA sample to nucleic acid probes to determine if the patient has a CYP2D6 poor metabolizer genotype; and wherein the CYP2D6 poor metabolizer genotype is one of the CYP2D6G1846A genotype or the CYP2D6C100T genotype.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
3. The method of claim 2, wherein the CYP2D6 poor metabolizer genotype is one of the CYP2D6G1846A (AA) genotype or the CYP2D6G1846A (AG) genotype.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
4. The method of claim 3, wherein the CYP2D6 poor metabolizer genotype is the CYP2D6G1846A (AA) genotype.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
5. The method of claim 2, wherein the CYP2D6 poor metabolizer genotype is one of the CYP2D6C100T (TT) genotype or the CYP2D6C100T (CT) genotype.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
6. The method of claim 5, wherein the CYP2D6 poor metabolizer genotype is the CYP2D6C100T (TT) genotype.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
7. The method of claim 1, wherein the step of internally administering iloperidone to the patient in an amount of 12 mg/day or less comprises internally administering iloperidone to the patient in an amount of 6 mg or less b.i.d.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
8. The method of claim 2, wherein, if the patient has a CYP2D6 poor metabolizer 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_420_41}{\*\bkmkend co_pp_sp_7903_420_41}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*420
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 genotype, then internally administering iloperidone to the patient in an amount of 6 mg b.i.d.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
9. A method of treating a patient who is suffering from a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic86e7a73475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
schizoaffective disorder
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, depression, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibbea96ff475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Tourette\rquote s syndrome
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic6c75a10475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
psychotic disorder
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 or a delusional disorder, the method comprising: determining if the patient is a CYP2D6 poor metabolizer by obtaining or having obtained a biological sample from the patient, and performing or having performed a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ib3510dc6475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
genotyping
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 assay on the biological sample to determine whether the patient has a CYP2D6 poor metabolizer genotype, and if the patient is a CYP2D6 poor metabolizer, then internally administering iloperidone to the patient in an amount of up to 12 mg/day, and if the patient is not a CYP2D6 poor metabolizer, then internally administering iloperidone to the patient in an amount of greater than 12 mg/day, up to 24 mg/day.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
11. The method of claim 9, wherein the CYP2D6 poor metabolizer genotype is one of: B-3 CYP2D6G1846A (AA), CYP2D6G1846A (AG), CYP2D6C100T (TT), or CYP2D6C100T (CT).
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
12. The method of claim 9, wherein the method comprises: if the patient is a CYP2D6 poor metabolizer, then internally administering the iloperidone to the patient in an amount of 6 mg b.i.d.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
13. A method of treating a patient who is suffering from a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic86e7a73475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
schizoaffective disorder
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, depression, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibbea96ff475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Tourette\rquote s syndrome
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic6c75a10475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
psychotic disorder
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 or a delusional disorder, the method comprising: determining if the patient is at risk for iloperidone-induced QTc prolongation by obtaining or having obtained a biological sample from the patient, and performing or having performed a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ib3510dc6475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
genotyping
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 assay on the biological sample to determine whether the patient has a CYP2D6 poor metabolizer genotype, wherein the presence of a CYP2D6 poor metabolizer genotype indicates risk for iloperidone-induced QTc prolongation, and if the patient is at risk for iloperidone-induced QTc prolongation, then internally administering iloperidone to the patient in an amount of up to 12 mg/day, and if the patient is not at risk for iloperidone-induced QTc prolongation, then internally administering iloperidone to the patient in an amount of greater than 12 mg/day, up to 24 mg/day.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
16. The method of claim 13, wherein the method comprises: if the patient is at risk for iloperidone-induced QTc prolongation, then internally administering the iloperidone to the patient in an amount of 6 mg b.i.d. claims 1-9, 11-13, and 16 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ife2d2e511a0311ebb27dc1895c097}{\*\bkmkend co_anchor_Ife2d2e511a0311ebb27dc1895c097}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ife2d2e511a0311ebb27dc1895c097}{\*\bkmkend co_anchor_Ife2d2e511a0311ebb27dc1895c097}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
D. FANAPT\u174\'3f and Roxane\rquote s ANDA
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
20. FANAPT\u174\'3f (iloperidone) is an atypical antipsychotic approved for the treatment of patients with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ad584c475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
schizophrenia
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
. Vanda offers for sale and sells FANAPT\u174\'3f in the United States.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
21. On May 6, 2009, the Food and Drug Administration (\u8220\'3fFDA\u8221\'3f) approved Vanda\rquote s new drug application 22-192 for FANAPT\u174\'3f (iloperidone) in its 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg strengths under \u167\'3f 505(b) of the Federal Food, Drug, and Cosmetic Act (the \u8220\'3fFFDCA\u8221\'3f), 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=21USCAS355&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_a83b000018c76" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
21 U.S.C. \u167\'3f 355(b)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, for the treatment of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ad584c475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
schizophrenia
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 (\u8220\'3fFANAPT\u174\'3f NDA\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
22. Vanda owns the FANAPT\u174\'3f NDA.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
23. The prescribing information for FANAPT\u174\'3f (\u8220\'3fFANAPT\u174\'3f Label\u8221\'3f) states in part that \u8220\'3fFANAPT\u174\'3f tablets are indicated for the treatment of adults with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ad584c475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
schizophrenia
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
.\u8221\'3f \u167\'3f 1.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
24. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ad584c475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Schizophrenia
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic6c75a10475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
psychotic disorder
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
25. The FANAPT\u174\'3f Label states in part that \u8220\'3fFANAPT is associated with prolongation of the QTc interval.\u8221\'3f \u167\'3f 1.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
26. The FANAPT\u174\'3f Label states in part that \u8220\'3fProlongation of the QTc interval is associated in some other drugs with the 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_421_41}{\*\bkmkend co_pp_sp_7903_421_41}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*421
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ability to cause torsade de pointes-type 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic3f3c7d1475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
arrhythmia
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, a potentially fatal 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib4d69be8475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
polymorphic ventricular tachycardia
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 which can result in sudden death.\u8221\'3f \u167\'3f 1.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
27. The FANAPT\u174\'3f Label states in part that \u8220\'3fThe recommended target dosage of FANAPT tablets is 12 to 24 mg/day administered twice daily.\u8221\'3f Dosage and Administration.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
28. The FANAPT\u174\'3f Label states in part that \u8220\'3fThe maximum recommended dose [of FANAPT\u174\'3f (iloperidone) ] is 12 mg twice daily (24 mg/day).\u8221\'3f \u167\'3f 2.1.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
29. The FANAPT\u174\'3f Label states in part that \u8220\'3fFANAPT dose should be reduced by one-half for poor metabolizers of CYP2D6.\u8221\'3f \u167\'3f 2.2.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
30. The FANAPT\u174\'3f Label states in part that \u8220\'3fIloperidone is metabolized primarily by 3 biotransformation pathways: carbonyl reduction, hydroxylation (mediated by CYP2D6) and O-demethylation (mediated by CYP3A4).\u8221\'3f \u167\'3f 12.3.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
31. The FANAPT\u174\'3f Label states in part that \u8220\'3fApproximately 7%\u8212\'3f10% of Caucasians and 3%\u8212\'3f8% of black/African Americans lack the capacity to metabolize CYP2D6 substrates and are classified as poor metabolizers (PM), whereas the rest are intermediate, extensive or ultrarapid metabolizers.\u8221\'3f \u167\'3f 12.3.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
32. The FANAPT\u174\'3f Label states in part that \u8220\'3fPMs of CYP2D6 have higher exposure to iloperidone compared with EMs and PMs should have their dose reduced by one-half. Laboratory tests are available to identify CYP2D6 PMs.\u8221\'3f \u167\'3f 12.3.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
33. The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2009579817&pubNum=0004073&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Id04ab71917f711db9a6ba61a2ffc7828&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 198 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are listed in connection with FANAPT\u174\'3f in FDA\rquote s publication, \u8220\'3fApproved Drug Products with Therapeutic Equivalence Evaluations,\u8221\'3f referred to as the \u8220\'3fOrange Book.\u8221\'3f The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 was listed in the Orange Book on or about January 15, 2015, after both of these lawsuits were filed.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
34. Roxane filed Abbreviated New Drug Application No. 20-5480 (the \u8220\'3fRoxane AND A\u8221\'3f) under \u167\'3f 505(j) of the FFDCA to obtain approval to commercially manufacture and sell generic iloperidone tablets in 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg strengths for the treatment of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ad584c475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
schizophrenia
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, prior to the expiration of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2009579817&pubNum=0004073&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Id04ab71917f711db9a6ba61a2ffc7828&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 198 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat32 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. On October 17, 2013, Roxane sent Novartis and Aventisub II Inc. a Patent Notice pursuant to \u167\'3f 505(j)(2)(B)(ii) asserting that the claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2009579817&pubNum=0004073&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Id04ab71917f711db9a6ba61a2ffc7828&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 198 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are invalid under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS103&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat32 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 103
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
36. On May 6, 2015, Roxane sent Vanda a Patent Notice pursuant to \u167\'3f 505(j)(2)(B)(ii) asserting that Roxane\rquote s iloperidone label does not induce infringement of any claim of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and that the claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are invalid under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat32 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat32 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat32 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS103&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
103
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
37. If the Roxane ANDA is approved, Roxane will sell generic iloperidone tablets in 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg strengths for the treatment of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ad584c475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
schizophrenia
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 in the United States.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
38. By law, Roxane\rquote s label for its generic iloperidone product must include information from the label for the reference listed drug \u8220\'3fexcept for changes required because of differences approved under a petition filed under subparagraph (C) or because the new drug and the listed drug are produced or distributed by different manufacturers.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=21USCAS355&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_b9020000c7341" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
21 U.S.C. \u167\'3f 355(j)(2)(A)(v)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
39. The prescribing information proposed in the Roxane ANDA states in part that \u8220\'3fIloperidone tablets are indicated for the treatment of adults with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ad584c475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
schizophrenia
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
.\u8221\'3f \u167\'3f 1.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
40. The prescribing information proposed in the Roxane ANDA states in part that \u8220\'3fIloperidone is associated with prolongation of the QTc interval.\u8221\'3f \u167\'3f 1.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_422_41}{\*\bkmkend co_pp_sp_7903_422_41}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*422
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 41. The prescribing information proposed in the Roxane ANDA states in part that \u8220\'3fProlongation of the QTc interval is associated in some other drugs with the ability to cause torsade de pointes-type 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic3f3c7d1475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
arrhythmia
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, a potentially fatal 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib4d69be8475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
polymorphic ventricular tachycardia
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 which can result in sudden death.\u8221\'3f \u167\'3f 1.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
42. The prescribing information proposed in the Roxane ANDA states in part that \u8220\'3fThe recommended target dosage of iloperidone tablets is 12 to 24 mg/day administered twice daily.\u8221\'3f Dosage and Administration.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
43. The prescribing information proposed in the Roxane ANDA states in part that \u8220\'3fThe maximum recommended dose [of iloperidone] is 12 mg twice daily (24 mg/day).\u8221\'3f \u167\'3f 2.1.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
44. The prescribing information proposed in the Roxane ANDA states in part that \u8220\'3fIloperidone dose should be reduced by one-half for poor metabolizers of CYP2D6.\u8221\'3f \u167\'3f 2.2.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
45. The prescribing information proposed in the Roxane ANDA states in part that \u8220\'3fIloperidone is metabolized primarily by 3 biotransformation pathways: carbonyl reduction, hydroxylation (mediated by CYP2D6) and O-demethylation (mediated by CYP3A4).\u8221\'3f \u167\'3f 12.3.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
46. The prescribing information proposed in the Roxane ANDA states in part that \u8220\'3fApproximately 7% to 10% of Caucasians and 3% to 8% of black/African Americans lack the capacity to metabolize CYP2D6 substrates and are classified as poor metabolizers (PM), whereas the rest are intermediate, extensive or ultrarapid metabolizers.\u8221\'3f \u167\'3f 12.3.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
47. The prescribing information proposed in the Roxane ANDA states in part that \u8220\'3fPMs of CYP2D6 have higher exposure to iloperidone compared with EMs and PMs should have their dose reduced by one-half. Laboratory tests are available to identify CYP2D6 PMs.\u8221\'3f \u167\'3f 12.3.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
48. By letter dated October 17, 2013 (\u8220\'3fRoxane Notice Letter\u8221\'3f), Roxane notified Aventisub that Roxane had filed the Roxane ANDA seeking approval to manufacture, use, offer to sell, and sell a generic version of FANAPT\u174\'3f (iloperidone) in 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg strengths for the treatment of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ad584c475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
schizophrenia
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 before the expiration of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2009579817&pubNum=0004073&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Id04ab71917f711db9a6ba61a2ffc7828&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 198 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
49. Plaintiffs assert infringement of the following claims against Roxane: claim 3 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2009579817&pubNum=0004073&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Id04ab71917f711db9a6ba61a2ffc7828&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 198 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and claims 1-9, 11-13, and 16 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
50. Plaintiffs commenced Civil Action No. 13\u8211\'3f1973 regarding infringement of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2009579817&pubNum=0004073&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Id04ab71917f711db9a6ba61a2ffc7828&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 198 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 on November 25, 2013, within 45 days from Aventisub\rquote s receipt of the Roxane Notice Letter.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
51. Plaintiff Vanda commenced Civil Action No. 14\u8211\'3f757 regarding infringement of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 on June 16, 2014.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ife3915311a0311ebb27dc1895c097}{\*\bkmkend co_anchor_Ife3915311a0311ebb27dc1895c097}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ife3915311a0311ebb27dc1895c097}{\*\bkmkend co_anchor_Ife3915311a0311ebb27dc1895c097}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
III. DISCUSSION AND CONCLUSIONS OF LAW
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The court has jurisdiction over the subject matter of this action pursuant to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=28USCAS1331&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
28 U.S.C. \u167\'3f\u167\'3f 1331
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=28USCAS1338&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_8b3b0000958a4" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
1338(a)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Venue is proper under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=28USCAS1391&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_a83b000018c76" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
28 U.S.C. \u167\'3f\u167\'3f 1391(b)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=28USCAS1391&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_4b24000003ba5" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(c)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=28USCAS1391&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_5ba1000067d06" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(d)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=28USCAS1400&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_a83b000018c76" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
1400(b)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. After having considered the entire record in this case, the substantial evidence in the record, the parties\rquote  post-trial submissions, and the applicable law, the court concludes that: (1) all asserted claims of the patents-in-suit are valid; (2) Roxane\rquote s proposed products induce infringement of the asserted claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; and (3) Roxane\rquote s proposed products do not contributorily infringe the asserted claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The court\rquote s reasoning follows.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ife3a74c11a0311ebb27dc1895c097}{\*\bkmkend co_anchor_Ife3a74c11a0311ebb27dc1895c097}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ife3a74c11a0311ebb27dc1895c097}{\*\bkmkend co_anchor_Ife3a74c11a0311ebb27dc1895c097}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_423_41}{\*\bkmkend co_pp_sp_7903_423_41}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*423
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
A. Obviousness
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
1. 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa200 \sb400 
The Legal Standard
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf23 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B12039653953_41}{\*\bkmkend co_anchor_B12039653953_41}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS103&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat32 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 103(a)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, a patent may not be obtained \u8220\'3fif the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art\u8221\'3f (\u8220\'3fPOSA\u8221\'3f). 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS103&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat32 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 103(a)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Obviousness is a question of law that is predicated on several factual inquires. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997200571&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1479&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1479" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Richardson\u8211\'3fVicks v. Upjohn Co.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 122 F.3d 1476, 1479 (Fed.Cir.1997)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Specifically, the trier of fact is directed to assess four considerations: (1) the scope and content of the prior art; (2) the level of ordinary skill in the art; (3) the differences between the claimed subject matter and the prior art; and (4) secondary considerations of non-obviousness, such as commercial success, long-felt but unsolved need, failure of others, acquiescence of others in the industry that the patent is valid, and unexpected results. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1966112593&pubNum=0000780&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_780_17&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_17" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Graham v. John Deere Co.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 383 U.S. 1, 17\u8211\'3f18, 86 S.Ct. 684, 15 L.Ed.2d 545 (1966)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf23 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B22039653953_41}{\*\bkmkend co_anchor_B22039653953_41}
}
{\b0 \cf23 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B32039653953_41}{\*\bkmkend co_anchor_B32039653953_41}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8220\'3fA patent shall be presumed valid.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS282&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_8b3b0000958a4" }{\fldrslt 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat32 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 282(a)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. A party seeking to challenge the validity of a patent based on obviousness must demonstrate by \u8220\'3fclear and convincing evidence\u8221\'3f
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00032039653953_ID0EJ5CI_41}{\*\bkmkend co_fnRef_B00032039653953_ID0EJ5CI_41}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00032039653953_41" }{\fldrslt 
{\super \b0 \cf23 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
3
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 that the invention described in the patent would have been obvious to a person of ordinary skill in the art at the time the invention was made. Importantly, in determining what would have been obvious to one of ordinary skill in the art, the use of hindsight is not permitted. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012126122&pubNum=0000780&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_780_421&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_421" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
KSR Int\rquote l Co. v. Teleflex, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 550 U.S. 398, 421, 127 S.Ct. 1727, 167 L.Ed.2d 705 (2007)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (cautioning the trier of fact against \u8220\'3fthe distortion caused by hindsight bias\u8221\'3f and \u8220\'3farguments reliant upon 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
ex post
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 reasoning\u8221\'3f in determining obviousness). In 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012126122&pubNum=0000780&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
KSR
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the Supreme Court rejected the rigid application of the principle that there should be an explicit teaching, suggestion, or motivation in the prior art, the \u8220\'3fTSM test,\u8221\'3f in order to find obviousness. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012126122&pubNum=0000708&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 415, 127 S.Ct. 1727
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012126122&pubNum=0000780&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
KSR
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Court acknowledged, however, the importance of identifying \u8220\'3fa reason that would have prompted a person of ordinary skill in the relevant field to combine the elements in the way the claimed new invention does.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012126122&pubNum=0000708&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 418, 127 S.Ct. 1727
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf23 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B42039653953_41}{\*\bkmkend co_anchor_B42039653953_41}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8220\'3fObviousness does not require absolute predictability of success,\u8221\'3f but rather, requires \u8220\'3fa reasonable expectation of success.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2008351576&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1165&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1165" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Medichem, S.A. v. Rolabo, S.L.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 437 F.3d 1157, 1165 (Fed.Cir.2006)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1988103052&pubNum=0000350&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_350_903&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_903" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
In re O\rquote Farrell
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 853 F.2d 894, 903\u8211\'3f04 (Fed.Cir.1988)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). To this end, obviousness \u8220\'3fcannot be avoided simply by a showing of some degree of unpredictability in the art so long as there was a reasonable probability of success.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2011748791&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1364&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1364" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Pfizer, Inc. v. Apotex, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 480 F.3d 1348, 1364 (Fed.Cir.2007)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Moreover, while the Federal Circuit has noted that pharmaceuticals can be an \u8220\'3funpredictable art\u8221\'3f to the extent that results may be unexpected, it also recognizes that, per 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012126122&pubNum=0000780&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
KSR
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, evidence of a \u8220\'3ffinite number of identified, predictable solutions\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012126122&pubNum=0000780&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_780_421&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_421" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
KSR Int\rquote l Co.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 550 U.S. at 421, 127 S.Ct. 1727
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, \u8220\'3fmight support an inference of obviousness.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2015619459&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1364&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1364" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ortho\u8211\'3fMcNeil Pharmaceutical, Inc. v. Mylan Laboratories, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 520 F.3d 1358, 1364 (Fed.Cir.2008)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ife42d9311a0311ebb27dc1895c097}{\*\bkmkend co_anchor_Ife42d9311a0311ebb27dc1895c097}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
2. 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa200 \sb400 
The Level of Ordinary Skill in the Art
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
With regard to the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2009579817&pubNum=0004073&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Id04ab71917f711db9a6ba61a2ffc7828&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 198 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the parties agree that a person of ordinary skill in the art working in the field of the 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_424_41}{\*\bkmkend co_pp_sp_7903_424_41}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*424
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2009579817&pubNum=0004073&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Id04ab71917f711db9a6ba61a2ffc7828&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 198 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 would have an advanced degree in medicinal chemistry and/or pharmacology with some experience with the design and/or synthesis of antipsychotic drugs.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00042039653953_ID0EQIDI_41}{\*\bkmkend co_fnRef_B00042039653953_ID0EQIDI_41}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00042039653953_41" }{\fldrslt 
{\super \b0 \cf23 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
4
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
With regard to the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, a person of ordinary skill in the art would: (1) understand pharmacogenetics; or (2) have a degree in medicine, pharmacy, pharmacology, or a related field and practical experience in the field of psychiatry and/or clinical pharmacology, including pharmacogenomics. While the parties disagree, the court concludes that the parties\rquote  definitions of a person of ordinary skill in the art do not differ in a meaningful way.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00052039653953_ID0EDKDI_41}{\*\bkmkend co_fnRef_B00052039653953_ID0EDKDI_41}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00052039653953_41" }{\fldrslt 
{\super \b0 \cf23 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
5
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ife4746011a0311ebb27dc1895c097}{\*\bkmkend co_anchor_Ife4746011a0311ebb27dc1895c097}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
3. 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa200 \sb400 
Nonobviousness of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2009579817&pubNum=0004073&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Id04ab71917f711db9a6ba61a2ffc7828&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 198 Patent
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf23 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B52039653953_41}{\*\bkmkend co_anchor_B52039653953_41}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Roxane challenges the validity of claim 3 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2009579817&pubNum=0004073&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Id04ab71917f711db9a6ba61a2ffc7828&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 198 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, arguing that it is obvious in light of the prior art as of the May 19, 1989 priority date. (D.I. 185 at 10.) The parties agree that at the time of the invention, a person of ordinary skill in the art would have recognized the need for an atypical antipsychotic. Tr. at 672:15\u8211\'3f22; 719:22\u8211\'3f720:12 (Sargent); 596:5\u8211\'3f8 (Ratain); 767:22\u8211\'3f768:2 (Strupczewski); 822:4\u8211\'3f13 (Bartlett); 893:21\u8211\'3f894:6 (Roth). According to Roxane, in 1989, after Jansseh Pharmaceuticals announced the discovery of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3ba713fa475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
risperidone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, a person of ordinary skill in the art searching for an atypical antipsychotic would focus on two compounds, which it labels compounds A and B, because they were known antipsychotics that resembled 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3ba713fa475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
risperidone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. (D.I. 179 at 34.) In particular, Roxane claims that a publication in the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Journal of Medicinal Chemistry
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 by Robert Duncan and Grover C. Helsley (JX-40), would teach a person of ordinary skill in the art to look to Compounds A and B. Dr. Sargent testified that the discovery of risperidone would lead a person of ordinary skill back to Helsley to experiment with a closely-related compound, Compound A. Indeed, Compound B was investigated as a potential antipsychotic following the publication of Helsley under the name \u8220\'3flenperone.\u8221\'3f Finally, according to Dr. Sargent, a person ordinarily skilled in the art could easily modify a butyrophenone compound such as Compound A or B by replacing its benzoyl moiety with a benzisoxazole moiety. (D.I. 185 at 14); Tr. at 692:10\u8211\'3f12, 693:10\u8211\'3f17 (Sargent). Thus, Roxane contends that a person of ordinary skill in the art had both a lead compound and the motivation to modify the lead compound.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In contrast, the Plaintiffs dispute that Compound B would lead a person of ordinary skill in the art to Compound A. (D.I. 84 at 14.) The Plaintiffs note that lenperone had caused extremely serious side effects, such that the skilled artisan would avoid it and its related compounds. Tr. at 910:5\u8211\'3f12 (Roth). In an open-label clinical trial published in 1975, the ten patients treated with lenperone experienced nineteen serious cardiac side effects. Tr. at 908:7\u8211\'3f910:3 (Roth) (citing PX-137 (Harris (1975)); 754:10\u8211\'3f16 (Sargent). Lenperone was also associated with moderate sedation. Tr. at 754:17\u8211\'3f755:6 (Sargent). Moreover, according to the Plaintiffs, lenperone was known to induce 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib89aa910475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
catalepsy
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Tr. at 904:24\u8211\'3f905:3, 906:12\u8211\'3f18 (Roth) (citing JX-66).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_425_41}{\*\bkmkend co_pp_sp_7903_425_41}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*425
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The Plaintiffs further assert that Compound A was not known to be an antipsychotic. Rather, it was known to have tranquilizing activity and strong sedative effects, neither of which suggests its use as an antipsychotic. Tr. at 898:20\u8211\'3f903:23 (Roth) (citing DTX-143; JX-40; JX-63; JX-66). In addition, Dr. Roth testified that Compound A would not be expected to have atypical antipsychotic activity. Tr. at 898:20\u8211\'3f903:23 (Roth). Finally, even if a skilled artisan happened to start with Compound A in 1989, the Plaintiffs argue that there would be no motivation to make the bioisosteric substitution out of the many possible modifications to butyrophenones that were known. Tr. at 825:24\u8211\'3f830:1 (Bartlett); 664:24\u8211\'3f665:11 (Sargent); 839:16\u8211\'3f25 (Bartlett).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The court does not find Dr. Sargent\rquote s testimony to be credible. Medicinal chemists spent decades and considerable resources trying to find a successor to clozapine, including Dr. Sargent, Tr. at 719:11\u8211\'3f21 (Sargent); 894:3\u8211\'3f7 (Roth), yet there is no evidence that anyone actually acted in the way that his theory predicts. Tr. at 760:7\u8211\'3f11 (Sargent). Instead, the court is persuaded by the Plaintiffs\rquote  argument that a person ordinarily skilled in the art in 1989 seeking to synthesize a new atypical antipsychotic would start with a compound known to have atypical activity, which would exclude Compound A. (D.I. 184 at 14\u8211\'3f15.) 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022953027&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1354&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1354" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Daiichi Sankyo Co. v. Matrix Labs., Ltd.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 619 F.3d 1346, 1354 (Fed.Cir.2010)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (it is the \u8220\'3fpossession of promising useful properties in a lead compound that motivates a chemist to make structurally similar compounds.\u8221\'3f). As the Federal Circuit has cautioned, the reason to select a compound as a lead compound depends on more than just structural similarity, but also knowledge in the art of the functional properties and limitations of the prior art compounds. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2010984122&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1377&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1377" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Eli Lilly and Co. v. Zenith Goldline Pharma., Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 471 F.3d 1369, 1377\u8211\'3f79 (Fed.Cir.2006)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In addition, Roxane fails to demonstrate that benzisoxazole modifications were then known to solve any of the demonstrated side effects associated with Compound B. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012564789&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1357&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1357" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Takeda Chem. Indus., Ltd. v. Alphapharm Pty., Ltd.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 492 F.3d 1350, 1357 (Fed.Cir.2007)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (finding it necessary to identify some reason that would have led a chemist to modify a known compound in a particular manner to establish prima facie obviousness of a new claimed compound). The court concludes that Roxane\rquote s argument is highly influenced by hindsight bias. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022953027&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1354&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1354" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Daiichi Sankyo Co.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 619 F.3d at 1354
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fthe attribution of a compound as a lead compound after the fact must avoid hindsight bias; it must look at the state of the art at the time the invention was made to find a motivation to select and then modify a lead compound to arrive at the claimed invention.\u8221\'3f) (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2015619459&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1364&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1364" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ortho\u8211\'3fMcNeil Pharm., Inc. v. Mylan Labs., Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 520 F.3d 1358, 1364 (Fed.Cir.2008)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ife510a011a0311ebb27dc1895c097}{\*\bkmkend co_anchor_Ife510a011a0311ebb27dc1895c097}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
4. 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa200 \sb400 
Nonobviousness of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf23 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B62039653953_41}{\*\bkmkend co_anchor_B62039653953_41}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Here, the court feels it necessary to provide a brief background about the claimed invention. Genetic mutations for the enzyme CYP2D6 are associated with an increased risk of iloperidone-induced QTc prolongation. JX-1. Many people are CYP2D6 poor metabolizers. JX-1 at 1:53\u8211\'3f61. This can alter both the performance and side-effect profile of the drug. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, e.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Tr. at 912:3\u8211\'3f7 (Roth). Iloperidone is metabolized into the P95 metabolite by the enzyme CYPD26. The claimed invention relies on the relationship between the ratio of P95 and P88 metabolites in the iloperidone metabolic pathway in the blood and the risk of QTc prolongation in iloperidone patients. 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
JX-1.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Roxane asserts the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 invention is obvious because a POSA would have known to study the implications for iloperidone metabolism of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=I777c6a64995711de9b8c850332338889&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
mutations in the genes
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 for the CYP2D6 enzyme. (D.I. 179 at 22.) 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_426_41}{\*\bkmkend co_pp_sp_7903_426_41}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*426
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Roxane relies on the prior art teachings from E. Mutlib & J. T. Klein, \u8220\'3fApplication of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Iab95af31475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Liquid Chromatography
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
/
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Iaf7c5f07475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Mass Spectrometry
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in Accelerating the Identification of Human Liver Cytochrome P450 Isoforms Involved in the Metabolism of Iloperidone,\u8221\'3f in light of 1999 FDA Guidance for Industry. JX-68; DTX-118. According to Roxane, Mutlib taught that iloperidone had completed Phase II clinical trials as a potential atypical antipsychotic with a lower risk of side effects. Tr. at 528:14-529:3 (Ratain); JX-68 at 1285. Mutlib also taught that CYP2D6 was important in the metabolism of iloperidone. Tr. at 530:23-531:13 (Ratain). Mutlib reported the results of a study of the metabolism of iloperidone in human liver microsomes to define its metabolic pathways, Tr. at 531:14-20 (Ratain); JX-68 at Abstract, and Mutlib disclosed that metabolites 2 and 4 were formed by CYP3A4 and by the polymorph CYP2D6, respectively. Tr. at 531:21-23 (Ratain); JX-68 at Abstract. Dr. Ratain testified that, because it was known that CYP2D6 is important for the metabolism of iloperidone, a person ordinarily skilled in the art would be motivated to study it further. Tr. at 532:22\u8211\'3f25 (Ratain) (citing JX-68).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Roxane also reasons that the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is obvious because the FDA would have required clinical pharmacology studies to examine how the drug is metabolized. Tr. at 115:9-16 (Polymeropoulos), 977:24-979:4 (Guengerich); 533:1-24 (Ratain); DTX-76; DTX-118. Roxane posits that as of September 2004, these types of studies would be performed for any drug for which CYP2D6 was an important metabolic route of elimination. Tr. at 534:6-11 (Ratain). This process is exactly what Novartis did in its iloperidone clinical program. Tr. at 534:12-16 (Ratain).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Plaintiffs respond that the prior art does not teach that CYP2D6 is important in iloperidone metabolism in the body (in vivo). (D.I. 84 at 11); Tr. at 967:7\u8211\'3f25, 968:13\u8211\'3f17 (Guengerich). According to the Plaintiffs, although Mutlib discloses that CYP2D6 plays a role in metabolizing iloperidone in vitro, the authors did not recover any meaningful in vivo results. Tr. at 592:18\u8211\'3f593:14 (Ratain); 967:7\u8211\'3f969:1 (Guengerich). The FDA warns that \u8220\'3fWhen a difference arises between findings in vitro and in vivo, the results in vivo should always take precedence over studies in vitro.\u8221\'3f DTX-118. Vanda further contends the prior art suggested that CYP2D6 was not important in the metabolism of iloperidone. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, e.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, PX-154; JX-95; DTX-53.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Moreover, the Plaintiffs argue that it is often the case that no dosage adjustment is needed for CYP2D6 poor metabolizers. (D.I. 184 at 12.) 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, e.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, DTX-122 at 9; Tr. at 607:2\u8211\'3f17, 607:25\u8211\'3f608:4 (Ratain). According to the Plaintiffs, it was unpredictable whether any dosage adjustment would be needed for CYP2D6 poor metabolizers, much less the amount of adjustment needed to achieve the pharmacokinetic profile seen in normal metabolizers. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, e.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Tr. at 605:7\u8211\'3f606:3 (Ratain) (citing JX-95 at 11); 609:15\u8211\'3f610:24 (Ratain) (citing JX-79 at 7); 938:6\u8211\'3f16 (Roth). Nor was it clear that a dose adjustment would reduce QTc prolongation, claim the Plaintiffs, because not all side effects are dose-dependent. Tr. at 939:16\u8211\'3f22 (Roth); 1008:6\u8211\'3f10 (Guengerich). Furthermore, the Plaintiffs contend that because QTc side effects were so risky, a person ordinarily skilled in the art would be deterred from further investigation. 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Tr. at 939:2\u8211\'3f15 (Roth) (\u8220\'3fwhen we saw prolongation of a QT interval that was induced by a drug, we stopped the drug. We did not give\u8212\'3fwe did not lower the dose. We stopped it.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf23 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B72039653953_41}{\*\bkmkend co_anchor_B72039653953_41}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The court concludes that the level of clinical testing required and inherent unpredictability in this field make certain that the invention was not obvious. The court is particularly persuaded by the fact 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_427_41}{\*\bkmkend co_pp_sp_7903_427_41}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*427
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 that Novartis abandoned iloperidone in development because of QTc prolongation. Tr. at 85:14\u8211\'3f18 (Polymeropoulos); 366:11\u8211\'3f368:4 (Economou); 529:23\u8211\'3f530:3 (Ratain) (citing DTX-53). Even if Mutlib provided a basis for a POSA to focus a study on the implications for iloperidone metabolism of mutations in the genes for the CYP2D6, it would have been impossible to predict the results. Tr. at 915:22\u8211\'3f916:2, 919:10\u8211\'3f13 (Roth). A solution is not obvious simply because it was obvious to conduct experiments to try to solve the problem. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1988012887&pubNum=0000350&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_350_473&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_473" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
In re Dow Chem. Co.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 837 F.2d 469, 473 (Fed.Cir.1988)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3f[S]elective hindsight is no more applicable to the design of experiments than it is to the combination of prior art teachings.\u8221\'3f). In conclusion, the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is not invalid as obvious.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ife5a31c11a0311ebb27dc1895c097}{\*\bkmkend co_anchor_Ife5a31c11a0311ebb27dc1895c097}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
5. 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa200 \sb400 
Secondary Considerations of Nonobviousness
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf23 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B82039653953_41}{\*\bkmkend co_anchor_B82039653953_41}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Roxane has failed to make a 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
prima facie
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 showing of obviousness under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS103&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 103
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. However, even if Roxane had met its burden, the Plaintiffs effectively make the case that secondary considerations weigh against a finding of obviousness. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1966112593&pubNum=0000780&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_780_17&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_17" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Graham
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 383 U.S. at 17\u8211\'3f18, 86 S.Ct. 684
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Specifically, the Plaintiffs offer evidence of a long-felt need. As the Plaintiffs points out, Novartis abandoned iloperidone and sold it to Vanda for an up-front payment of $500,000. Tr. at 84:6\u8211\'3f85:13 (Polymeropoulos). Subsequently, Vanda was able to get FDA approval for iloperidone, based at least in part on Polymeropoulos\rquote s and Wolfgang\rquote s invention to reduce the side effects associated with QTc prolongation in order to safely treat patients suffering from 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ad584c475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
schizophrenia
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Tr. at 84:15\u8211\'3f22 (Polymeropoulos). After iloperidone was approved, Novartis paid Vanda $200,000,000 to reacquire rights to iloperidone and to market FANAPT\u174\'3f in the U.S. Tr. at 84:6\u8211\'3f85:13 (Polymeropoulos). The forty-fold increase in Novartis\rquote s valuation of the franchise is highly indicative of non-obviousness. While Roxane argues that 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ad584c475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
schizophrenia
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 continues to be difficult to treat, (D.I. 85 at 11), the court\rquote s analysis must consider whether the claimed invention represents an improvement from the prior art at the time, not whether the problem has been totally eliminated.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ife62e4511a0311ebb27dc1895c097}{\*\bkmkend co_anchor_Ife62e4511a0311ebb27dc1895c097}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ife62e4511a0311ebb27dc1895c097}{\*\bkmkend co_anchor_Ife62e4511a0311ebb27dc1895c097}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
B. Subject Matter Eligibility of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
\sb200 
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
1. 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa200 \sb400 
The Legal Standard
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf23 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B92039653953_41}{\*\bkmkend co_anchor_B92039653953_41}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat32 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Section
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat32 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 describes the general categories of patentable subject matter as \u8220\'3fany new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat32 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat32 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat32 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. There are, however, exceptions to these broad classifications. Under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat32 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat32 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, \u8220\'3flaws of nature, natural phenomena, and abstract ideas\u8221\'3f are not patentable. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1981109598&pubNum=0000780&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_780_185&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_185" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Diamond v. Diehr
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 450 U.S. 175, 185, 101 S.Ct. 1048, 67 L.Ed.2d 155 (1981)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The contours of these exceptions have been the subject of much debate in recent years. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1981109598&pubNum=0000780&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3f[W]e tread carefully in construing this exclusionary principle lest it swallow all of patent law. At some level, all inventions ... embody, use, reflect, rest upon, or apply laws of nature, natural phenomena, or abstract ideas.\u8221\'3f (internal citation and quotations marks omitted)).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf23 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B102039653953_41}{\*\bkmkend co_anchor_B102039653953_41}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Supreme Court\rquote s decision in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 reaffirmed the framework first outlined in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo Collaborative Services v. Prometheus Laboratories, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. 66, 132 S.Ct. 1289, 182 L.Ed.2d 321 (2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, used to \u8220\'3fdistinguish[ ] patents that claim laws of nature, natural phenomena, and abstract ideas from those that claim patent-eligible applications of those concepts.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_708_2355&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2355" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice Corp. Pty. v. CLS Bank Int\rquote l
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, \u8211\'3f\u8211\'3f\u8211\'3f U.S. \u8211\'3f\u8211\'3f\u8211\'3f\u8211\'3f, 134 S.Ct. 2347, 2355, 189 L.Ed.2d 296 (2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
First, we determine whether the claims at issue are directed to one of those 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_428_41}{\*\bkmkend co_pp_sp_7903_428_41}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*428
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 patent-ineligible concepts. If so, we then ask, what else is there in the claims before us? To answer that question, we consider the elements of each claim both individually and as an ordered combination to determine whether the additional elements transform the nature of the claim into a patent-eligible application.
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_708_1296&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1296" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo Collaborative Services
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 132 S.Ct. at 1296\u8211\'3f98
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (internal citations, quotations marks, and alterations omitted). Thus, the court must determine (1) if the patented technology touches upon ineligible subject matter, and (2) whether there are sufficient inventive elements such that the invention is \u8220\'3f \u8216\'3fsignificantly more\u8217\'3f than a patent on an ineligible concept.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034937126&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1255&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1255" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
DDR Holdings, LLC v. Hotels.com, L.P.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 773 F.3d 1245, 1255 (Fed.Cir.2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_708_2355&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2355" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 134 S.Ct. at 2355
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
); 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_708_2354&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2354" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 134 S.Ct. at 2354
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3f[A]n invention is not rendered ineligible for patent simply because it involves an abstract concept.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ife6974011a0311ebb27dc1895c097}{\*\bkmkend co_anchor_Ife6974011a0311ebb27dc1895c097}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
2. 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa200 \sb400 
The CYP2D6 Reaction
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Roxane\rquote s subject matter ineligibility argument is based upon the contention that the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is directed toward a patent ineligible subject, specifically a law of nature that it applies in a way that is routine and conventional. Roxane asserts that the patent embodies two laws of nature: (1) that mutations in the CYP2D6 genes can alter enzymatic activity, and (2) that a patient\rquote s CYP2D6 enzymatic activity affects their metabolism of iloperidone. Tr. at 621:19\u8211\'3f622:2 (Ratain). Thus, according to Roxane, all of the method-of-treatment claims depend on natural processes. (D.I. 184 at 9.) To this, Roxane insists that the Plaintiffs merely add a dose adjustment to reduce the risk of a side effect, which Roxane claims is routine and conventional activity. (D.I. 185 at 10); Tr. at 521:6-522:10 (Ratain). According to Roxane, a person ordinarily skilled in the art would naturally discover the invention in performing FDA-mandated studies. (D.I. 179 at 17); Tr. at 604:13\u8211\'3f19 (Ratain). Roxane\rquote s expert, Dr. Ratain, cited the prior art teaching from Goodman & Gilman\rquote s textbook as support for this view. DTX-79.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Plaintiffs respond that 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat32 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat32 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 forbids patent claims \u8220\'3fdirected to\u8221\'3f patent-ineligible concepts, not claims that merely \u8220\'3f
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
involve
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 a patent ineligible concept, because essentially every routinely patent-eligible claim involving physical products and actions involves a law of nature and/or natural phenomenon ....\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038839002&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1335&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1335" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Enfish, LLC v. Microsoft Corp.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 822 F.3d 1327, 1335 (Fed.Cir.2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The Plaintiffs argue that they have not sought to claim the use of biological sampling, or 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ib3510dc6475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
genotyping
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, or the relationship between iloperidone, CYP2D6 metabolism and QTc prolongation. (D.I. 178 at 23\u8211\'3f24.) According to the Plaintiffs, the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 was not the result of routine and conventional testing. Specifically, the Plaintiffs\rquote  expert, Dr. Charles McCulloch, testified that clinical-study design is not routine or conventional. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Tr. at 629:15\u8211\'3f21, 649:19\u8211\'3f650:7 (McCulloch). The Plaintiffs also cite evidence that adjusting the dose for CYP2D6 poor metabolizers does not actually lower the risk of QTc prolongation for many drugs, including for antipsychotics that are structurally similar to iloperidone. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Ex. A, Guengerich \u182\'3f\u182\'3f 84\u8211\'3f144, 155\u8211\'3f60; Ex. B, Roth \u182\'3f\u182\'3f 144\u8211\'3f62. Finally, the Plaintiffs point out that the U.S. Patent Office explicitly considered subject matter eligibility of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 claims in light of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo Collaborative Services
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and upheld the patentability of the claims after specific doses were added to the claims. Tr. at 521:6-21 (Ratain); JX-94 at 21; JX-20 at 2; DTX-82 at 2.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The court is persuaded that the asserted claims depend upon laws of nature. The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 describes the invention in terms of multiple natural relationships:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The present invention describes an association between genetic polymorphisms 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_429_41}{\*\bkmkend co_pp_sp_7903_429_41}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*429
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 in the CYP2D6 locus, corresponding increases in the concentrations of iloperidone or its metabolites, and the effect of such increases in concentrations on corrected QT (QTc) duration relative to baseline.
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
JX-1 at 2:34-38. The claims depend on the relationship between iloperidone, CYP2D6 metabolism, and QTc prolongation.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The issue is whether the claims incorporate some additional step sufficient to transform the claims, making them valid. In 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo Collaborative Services
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the Supreme Court considered patent claims describing the relationship between the ways in which thiopurine compounds are metabolized by the body and determined that this was a law of nature. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_708_1297&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1297" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1297
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The court found that to this law of nature, the claims merely added an \u8220\'3fadministering\u8221\'3f step, a \u8220\'3fdetermining\u8221\'3f step, and a \u8220\'3fwherein\u8221\'3f step. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038839002&pubNum=0000999&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The Court wrote that the \u8220\'3fdetermining\u8221\'3f step in that case instructed the practitioner to determine the level of the relevant metabolites in the blood, \u8220\'3fthrough whatever process the doctor or the laboratory wishes to use.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038839002&pubNum=0000999&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Thus, this step told doctors \u8220\'3fto engage in well-understood, routine, conventional activity previously engaged in by scientists who work in the field.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_708_1298&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1298" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1298
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The Court wrote: \u8220\'3fWe need not, and do not, now decide whether were the steps at issue here less conventional, these features of the claims would prove sufficient to invalidate them.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_708_1302&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1302" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1302
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The patent-at-issue in this case addresses natural relationships to which the claims add conducting CYP2D6 genotyping tests to determine the appropriate dose of iloperidone to reduce QTc-related risks. According to Roxane, these dosage adjustment limitations steps were routine and conventional activity. (D.I. 179 at 17.) Roxanne argues that Dr. Ratain testified that while exact dose reduction may not necessarily be ascertained without doing studies, the studies to determine the correct dose adjustment were routine. Tr. at 524:24-525:4 (Ratain). The Plaintiffs disagree, arguing that the tests to determine the dosage adjustments were far from routine; indeed Novartis\rquote  clinical trials attempted but failed to determine the relationship between QTc prolongation and CYP2D6 metabolism, a discovery it was highly motivated to find. Tr. at 617:18\u8211\'3f618:19 (Ratain).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The court finds that while it may have been conventional to investigate for side-effects, Roxane has not proven by clear and convincing evidence that the precise test and the discovered results were routine or conventional. The court finds it persuasive that the dosage step in the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 does not apply to all patients, but only a specific patient population based upon their genetic composition. The dosage step requires applying genetic tests in a highly specified way. Moreover, the process of using this genetic test to inform the dosage adjustment recited in the claims was not routine or conventional and amounted to more than a mere instruction to apply a natural relationship. 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
This combination of elements is sufficient to ensure that the claims amount to significantly more than just a natural law. As the Federal Circuit instructed in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Rapid Litig. Mgmt. Ltd. v. CellzDirect, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 827 F.3d 1042, No. 2015\u8211\'3f1570, 2016 WL 3606624 (Fed.Cir. July 5, 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, a \u8220\'3fparticular \u8216\'3fcombination of steps\u8217\'3f \u8221\'3f can lead to valid patent claims that depend upon a natural relationship. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000999&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_999_4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_999_4" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1048\u8211\'3f49, 2016 WL 3606624 at *4
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1981109598&pubNum=0000780&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_780_188&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_188" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Diehr
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 450 U.S. at 188, 101 S.Ct. 1048
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). This is true even though the individual steps may have been well known. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000999&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_999_7&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_999_7" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1051, 2016 WL 3606624 at *7
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8220\'3fTo require something more ... would be to discount the human ingenuity that comes from applying a natural discovery in a way that achieves a \u8216\'3fnew and useful end.\u8217\'3f \u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000780&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_430_41}{\*\bkmkend co_pp_sp_7903_430_41}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*430
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_708_2354&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2354" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 134 S.Ct. at 2354
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). Finally, the court is persuaded that the concern articulated in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 that \u8220\'3fpatent law not inhibit further discovery by improperly tying up the future use of laws of nature\u8221\'3f does not apply here, because the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 will not preempt biological sampling or genotyping. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_708_1301&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1301" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo Collaborative Servs.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 132 S.Ct. at 1301
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; (D.I. 178 at 24). Thus, the patent-at-issue is not invalid for lack of patentable subject matter.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ife7904611a0311ebb27dc1895c097}{\*\bkmkend co_anchor_Ife7904611a0311ebb27dc1895c097}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ife7904611a0311ebb27dc1895c097}{\*\bkmkend co_anchor_Ife7904611a0311ebb27dc1895c097}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
C. Written Description of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
\sb200 
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
1. 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa200 \sb400 
The Legal Standard
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf23 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B112039653953_41}{\*\bkmkend co_anchor_B112039653953_41}
}
{\b0 \cf23 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B122039653953_41}{\*\bkmkend co_anchor_B122039653953_41}
}
{\b0 \cf23 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B132039653953_41}{\*\bkmkend co_anchor_B132039653953_41}
}
{\b0 \cf23 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B142039653953_41}{\*\bkmkend co_anchor_B142039653953_41}
}
{\b0 \cf23 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B152039653953_41}{\*\bkmkend co_anchor_B152039653953_41}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
To meet the written description requirement of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS112&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat32 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 112
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the application must show that, as of the filing date, the applicants were in possession of the invention in question. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1991104450&pubNum=0000350&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_350_1563&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_1563" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Vas\u8211\'3fCath Inc. v. Mahurkar
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 935 F.2d 1555, 1563\u8211\'3f64 (Fed.Cir.1991)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. \u8220\'3f[T]he test for sufficiency is whether the disclosure of the application relied upon 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
reasonably conveys
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to those skilled in the art that the inventor had possession of the claimed subject matter as of the filing date.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2021584873&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1351&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1351" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ariad Pharm., Inc. v. Eli Lilly & Co.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 598 F.3d 1336, 1351 (Fed.Cir.2010)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (emphasis added). Although an exact definition of \u8220\'3fpossession\u8221\'3f can be elusive, in essence, \u8220\'3fthe specification must describe an invention understandable to [a] skilled artisan and show that the inventor actually invented the invention claimed.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2021584873&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 To this end, support in the written description must be based on what actually is disclosed, and not on an obvious variant of what is disclosed. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2021584873&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1352&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1352" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1352
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997062584&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1571&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1571" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Lockwood v. Am. Airlines, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 107 F.3d 1565, 1571\u8211\'3f72 (Fed.Cir.1997)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). Whether the written description requirement is met is a question of fact. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2021584873&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1351&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1351" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1351
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1985146638&pubNum=0000350&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_350_1575&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_1575" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ralston Purina Co. v. Far\u8211\'3fMar\u8211\'3fCo, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 772 F.2d 1570, 1575 (Fed.Cir.1985)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). The party challenging the sufficiency of a written description must establish by clear and convincing evidence that the claim is invalid or not entitled to an asserted filing date. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2017246969&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1329&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1329" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Tech. Licensing Corp. v. Videotek, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 545 F.3d 1316, 1329\u8211\'3f30 (Fed.Cir.2008)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ife7dbf511a0311ebb27dc1895c097}{\*\bkmkend co_anchor_Ife7dbf511a0311ebb27dc1895c097}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
2. 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa200 \sb400 
Dosage Range
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf23 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B162039653953_41}{\*\bkmkend co_anchor_B162039653953_41}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Roxane argues that there is no support for a dosage range of 12 mg/day or less. (D.I. 185 at 11\u8211\'3f12); Tr. at 535:24\u8211\'3f536:2, 5419\u8211\'3f17 (Ratain); 630:6\u8211\'3f9 (McCulloch). Specifically, Roxane contends that the data in the patent do not support the asserted claims. Tr. at 630:4\u8211\'3f9; 631:11\u8211\'3f632:11 (McCulloch); 535:20\u8211\'3f536:2 (Ratain). Dr. McCulloch testified that the 12 mg/day or less dosage threshold in the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is not supported because the claims are based on indirect relationships that lack statistical significance. Tr. at 637:23\u8211\'3f25 (McCulloch).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Plaintiffs dispute this assertion. (D.I. 184 at 25.) The Plaintiffs point out that the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 discloses a trend for higher QTc prolongation among genotypic CYP2D6 poor metabolizers given a 24 mg daily dose. 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Tr. at 647:22\u8211\'3f648:2 (McCulloch) (citing Table 6 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (JX-1 at 8:50\u8211\'3f66)). In addition, Drs. Polymeropoulos and Wolfgang determined that the intermediate biomarkers for CYP2D6 poor metabolism are the ratios of P88 to P95 concentrations in the blood, correlated to higher QTc, and thus support the conclusion that genotypic CYP2D6 poor metabolizers had increased risk of QTc prolongation. Tr. at 976:19\u8211\'3f977:13 (Guengerich) (citing JX-1 at col. 10). According to the Plaintiffs, the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 explicitly discloses the appropriate dosage range based on the P88 to P95 ratio in the blood. (D.I. 84 at 13.) 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, e.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, JX-1 at 11:25\u8211\'3f28; 9:42\u8211\'3f47 (\u8220\'3fan individual with a genotype associated with decreased CYP2D6 activity may receive a reduced dosage of 18, 12, or 6 mg per day\u8221\'3f); 9:34\u8211\'3f42. Table 3 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 demonstrates that CYP2D6 poor metabolizers have 1.5 to 3.5 times higher P88 concentrations than non-poor metabolizers, 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_431_41}{\*\bkmkend co_pp_sp_7903_431_41}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*431
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 which supports a 1.5 to 3.5 reduction in dose for CYP2D6 poor metabolizers. JX-1 at 70:50\u8211\'3f60; Tr. at 106:16\u8211\'3f107:17 (Polymeropoulos).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The court must agree with the Plaintiffs that this data is sufficient to support possession of the claimed dosage range, even if not statistically significant. The patent need only \u8220\'3freasonably convey[ ] to those skilled in the art that the inventor had possession of the claimed subject matter as of the filing date.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2021584873&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1351&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1351" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ariad Pharm. Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 598 F.3d at 1351
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (en banc). Indeed, the statute does not recognize \u8220\'3fexamples or an actual reduction to practice.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032909107&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1190&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1190" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alcon Research Ltd. v. Barr Labs., Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 745 F.3d 1180, 1190 (Fed.Cir.2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2021584873&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1350&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1350" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ariad
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 598 F.3d at 1350
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
)). Thus, Roxane has failed to prove that the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is invalid for lack of written description.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ife8400e11a0311ebb27dc1895c097}{\*\bkmkend co_anchor_Ife8400e11a0311ebb27dc1895c097}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ife8400e11a0311ebb27dc1895c097}{\*\bkmkend co_anchor_Ife8400e11a0311ebb27dc1895c097}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
D. Infringement
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
1. 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa200 \sb400 
The Legal Standard
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf23 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B172039653953_41}{\*\bkmkend co_anchor_B172039653953_41}
}
{\b0 \cf23 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B182039653953_41}{\*\bkmkend co_anchor_B182039653953_41}
}
{\b0 \cf23 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B192039653953_41}{\*\bkmkend co_anchor_B192039653953_41}
}
{\b0 \cf23 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B202039653953_41}{\*\bkmkend co_anchor_B202039653953_41}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The determination of whether an accused method infringes a claim in a patent has two steps: (1) construction of the claim to determine its meaning and scope; and (2) comparison of the properly construed claim to the method at issue. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997065557&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_731&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_731" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Tanabe Seiyaku Co. v. United States Int\rquote I Trade Comm\rquote n
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 109 F.3d 726, 731 (Fed.Cir.1997)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1995081690&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_976&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_976" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Markman v. Westview Instruments, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 52 F.3d 967, 976 (Fed.Cir.1995)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (en banc), 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
aff\rquote d
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1996098750&pubNum=0000708&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
517 U.S. 370, 116 S.Ct. 1384, 134 L.Ed.2d 577 (1996)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). The patent owner has the burden of proving by a preponderance of the evidence that \u8220\'3fevery limitation of the patent claims asserted to be infringed is found in the accused [method], either literally or by an equivalent.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1988130005&pubNum=0000350&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_350_889&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_889" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
SmithKline Diag., Inc. v. Helena Lab. Corp.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 859 F.2d 878, 889 (Fed.Cir.1988)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Under this standard, a patent owner does not have to produce definite proof of infringement, but must instead demonstrate that \u8220\'3finfringement was more likely than not to have occurred.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2007113614&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1341&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1341" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Warner\u8211\'3fLambert Co. v. Teva Pharms., USA, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 418 F.3d 1326, 1341 n. 15 (Fed.Cir.2005)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2001670552&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1336&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1336" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Advanced Cardiovascular Sys., Inc. v. Scimed Life Sys., Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 261 F.3d 1329, 1336 (Fed.Cir.2001)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). The application of a patent claim to an accused product is a fact-specific inquiry. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2001753299&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1332&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1332" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Kustom Signals, Inc. v. Applied Concepts, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 264 F.3d 1326, 1332 (Fed.Cir.2001)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf23 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B212039653953_41}{\*\bkmkend co_anchor_B212039653953_41}
}
{\b0 \cf23 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B222039653953_41}{\*\bkmkend co_anchor_B222039653953_41}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In the ANDA context, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_9e660000185f2" }{\fldrslt 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat32 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(e)(2)(A)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 provides that it shall be an act of infringement to submit an ANDA \u8220\'3fif the purpose of such submission is to obtain approval ... to engage in the commercial manufacture, use, or sale of a drug ... claimed in a patent or the use of which is claimed in a patent before the expiration of such patent.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_9e660000185f2" }{\fldrslt 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat32 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(e)(2)(A)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. More specifically, as it relates to the instant matter, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_a83b000018c76" }{\fldrslt 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat32 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(b)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 states that \u8220\'3f[w]hoever actively induces infringement of a patent shall be liable as an infringer.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_a83b000018c76" }{\fldrslt 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat32 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(b)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Inducement requires \u8220\'3factively and knowingly aiding and abetting another\rquote s direct infringement.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1990115683&pubNum=0000350&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_350_675&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_675" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
C.R. Bard, Inc. v. Advanced Cardiovascular Sys., Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 911 F.2d 670, 675 (Fed.Cir.1990)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. In the Hatch-Waxman context, \u8220\'3f[s]tatements in a package insert that encourage infringing use of a drug product are alone sufficient to establish intent to encourage direct infringement\u8221\'3f for purposes of inducement to infringe under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_a83b000018c76" }{\fldrslt 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat32 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(b)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019535705&pubNum=0004637&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_4637_570&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_4637_570" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Abraxis Bioscience, Inc. v. Navinta, LLC
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 640 F.Supp.2d 553, 570 (D.N.J.2009)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, rev\rquote d and vacated on other grounds, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2023636909&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
625 F.3d 1359 (Fed.Cir.2010)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2018851161&pubNum=0004637&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_4637_580&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_4637_580" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
AstraZeneca LP v. Apotex, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 623 F.Supp.2d 579, 580 (D.N.J.2009)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2002555369&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1305&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1305" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
3M Co. v. Chemque, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 303 F.3d 1294, 1305 (Fed.Cir.2002)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (defendant who is aware of a patent and supplies a product to a customer with instructions for use, which when followed lead to infringement, has encouraged acts constituting direct infringement).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_432_41}{\*\bkmkend co_pp_sp_7903_432_41}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*432
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b0 \cf23 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B232039653953_41}{\*\bkmkend co_anchor_B232039653953_41}
}
{\b0 \cf23 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B242039653953_41}{\*\bkmkend co_anchor_B242039653953_41}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Importantly, however, mere knowledge of possible infringement does not constitute inducement. Rather, the patentee must prove that the defendant\rquote s actions \u8220\'3finduced infringing acts 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
and
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 that [the defendant] knew or should have known that [its] actions would induce actual infringement.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1990151121&pubNum=0000350&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_350_553&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_553" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Manville Sales Corp. v. Paramount Sys., Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 917 F.2d 544, 553 (Fed.Cir.1990)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. In ANDA cases, the court must consider whether \u8220\'3fthe proposed label instructs users to perform the patented method,\u8221\'3f as well as whether the proposed label encourages others to practice the patented method. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2023571452&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1060&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1060" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
AstraZeneca LP v. Apotex, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 633 F.3d 1042, 1060 (Fed.Cir.2010)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019816886&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1329&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1329" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Vita\u8211\'3fMix Corp. v. Basic Holdings, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 581 F.3d 1317, 1329 n. 2 (Fed.Cir.2009)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
With respect to contributory infringement, under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_4b24000003ba5" }{\fldrslt 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat32 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(c)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, \u8220\'3f[w]hoever offers to sell or sells within the United States or imports into the United States a component of patented ... manufacture, combination or composition, or a material ... for use in practicing a patented process, constituting a material part of the infringement, knowing the same to be especially made or especially adapted for use in infringement of such patent, and not a staple article or commodity of commerce suitable for substantial noninfringing use,\u8221\'3f shall be considered \u8220\'3fa contributory infringer.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_4b24000003ba5" }{\fldrslt 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat32 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(c)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The Federal Circuit has clarified that, to establish contributory infringement, the patent owner must prove that: (1) there is direct infringement; (2) the accused infringer had knowledge of the patent at issue; (3) the component has no substantial noninfringing uses; and (4) \u8220\'3fthe component is a material part of the invention.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2023085180&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1326&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1326" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Fujitsu Ltd. v. Netgear Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 620 F.3d 1321, 1326 (Fed.Cir.2010)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019793361&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1320&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1320" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Lucent Techs. Inc. v. Gateway, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 580 F.3d 1301, 1320 (Fed.Cir.2009)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ife8f24711a0311ebb27dc1895c097}{\*\bkmkend co_anchor_Ife8f24711a0311ebb27dc1895c097}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
2. 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa200 \sb400 
Direct Infringement
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf23 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B252039653953_41}{\*\bkmkend co_anchor_B252039653953_41}
}
{\b0 \cf23 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B262039653953_41}{\*\bkmkend co_anchor_B262039653953_41}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
As a preliminary matter, Roxane argues there is no evidence of direct infringement of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. (D.I. 185 at 2.) Direct infringement is a required element to establish induced infringement. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2021511297&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_851&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_851" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
i4i Ltd. P\rquote ship v. Microsoft Corp.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 598 F.3d 831, 851 (Fed.Cir.2010)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. To satisfy the direct infringement requirement, the patentee \u8220\'3fmust either point to specific instances of direct infringement or show that the accused device necessarily infringes the patent in suit.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013160940&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1313&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1313" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
ACCO Brands, Inc. v. ABA Locks Mfr. Co.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 501 F.3d 1307, 1313 (Fed.Cir.2007)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2004278741&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1275&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1275" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Dynacore Holdings Corp. v. U.S. Philips Corp.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 363 F.3d 1263, 1275\u8211\'3f76 (Fed.Cir.2004)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). The Plaintiffs contend that Roxane\rquote s Proposed Label for iloperidone is the same as Vanda\rquote s FANAPT\u174\'3f Label and establishes that Roxane\rquote s product will infringe the asserted claims. Tr. at 368:11\u8211\'3f16 (Economou); 373:15\u8211\'3f374:4 (Smith); 569:21\u8211\'3f23 (Ratain).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf23 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B272039653953_41}{\*\bkmkend co_anchor_B272039653953_41}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The evidence at trial demonstrated that Roxane\rquote s Proposed Label satisfies claims 1\u8211\'3f9, 11\u8211\'3f13, 16 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 as construed in the court\rquote s 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1996098750&pubNum=0000780&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Markman
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 order. (D.I. 125.) Roxane\rquote s Label recommends that practitioners use iloperidone to treat patients suffering from 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ad584c475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
schizophrenia
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. JX-13 at \u167\'3f 1. The label recommends oral administration of iloperidone tablets at 12 to 24 mg/day to non-genotypic CYP2D6 poor metabolizers and 12 mg/day or less to genotypic CYP2D6 poor metabolizers. JX-13 at \u167\'3f 2.1-2.2. It also recommends that practitioners perform or have performed a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ib3510dc6475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
genotyping
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 assay to determine whether patients are CYP2D6 poor metabolizers. JX-13 at \u167\'3f 12.3. Section 5.2 of the label states that in an open-label study, \u8220\'3filoperidone was associated with QTc prolongation of 9 msec at an iloperidone dose of 12 mg twice daily,\u8221\'3f that \u8220\'3funder conditions of metabolic inhibition for both 2D6 and 3A4, iloperidone 12 mg twice daily was associated with a mean QTc increase from baseline of 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_433_41}{\*\bkmkend co_pp_sp_7903_433_41}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*433
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 about 19 msec,\u8221\'3f and therefore \u8220\'3fcaution is warranted when prescribing iloperidone ... in patients with reduced activity of CYP2D6.\u8221\'3f JX-13 at \u167\'3f 5.2. Section 12.3 states that \u8220\'3fPMs of CYP2D6 have higher exposure to iloperidone compared with EMs and PMs should have their dose reduced by one-half.\u8221\'3f JX-13 at \u167\'3f 12.3; Tr. at 231:20\u8211\'3f234:4 (Preskorn). The court is persuaded that the testimony presented at trial demonstrated by the preponderance of the evidence that when the label states that \u8220\'3flaboratory tests\u8221\'3f are available to identify poor metabolizers, the label is referring to \u8220\'3fgenotyping tests.\u8221\'3f Tr. at 567:5\u8211\'3f568:2 (Ratain); 234:15\u8211\'3f235:13 (Preskorn); 174:7\u8211\'3f24, 198:4\u8211\'3f200:7 (Kricka). Tr. at 190:14\u8211\'3f193:12 (Kricka); 235:18\u8211\'3f23, 236:15\u8211\'3f19 (Preskorn) (all commercially available laboratory tests to determine whether a patient is a genotypic CYP2D6 poor metabolizer involve genotyping). Under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_9e660000185f2" }{\fldrslt 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat32 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(e)(2)(A)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, it is an act of infringement to file an ANDA application \u8220\'3ffor a drug claimed in a patent or the use of which is claimed in a patent.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_9e660000185f2" }{\fldrslt 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat32 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(e)(2)(A)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Thus, Roxane\rquote s submission of a paragraph IV certification for the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is an act of infringement. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, e.g.,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1995220011&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1131&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1131" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Bristol\u8211\'3fMyers Squibb Co. v. Royce Labs.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 69 F.3d 1130, 1131 (Fed.Cir.1995)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fInclusion of a paragraph IV certification in an ANDA, however, is deemed an act of infringement.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Roxane argues that it is impossible for its products to infringe the asserted claims because doctors do not actually administer a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ib3510dc6475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
genotyping
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 test and administer up to 12 mg/day of iloperidone to genotypic CYP2D6 poor metabolizers and therefore do not infringe all of the claims. (D.I. 185 at 2.) The Plaintiffs disagree, relying on the testimony of Dr. Alva. (D.I. 184 at 6\u8211\'3f7.) Dr. Alva\rquote s patient records and testimony confirm that he has practiced the steps of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 claims. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
) He testified that he genotypes his patients and he specifically identified a patient for whom he exceeded 12mg/day of iloperidone only after determining through genotyping that the patient was not a poor metabolizer. Tr. at 322:7\u8211\'3f326:17 (Alva). The court found Dr. Alva\rquote s testimony credible. Thus, the court finds that there is sufficient evidence to establish direct infringement.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ife989a511a0311ebb27dc1895c097}{\*\bkmkend co_anchor_Ife989a511a0311ebb27dc1895c097}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
3. 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa200 \sb400 
Induced Infringement
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf23 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B282039653953_41}{\*\bkmkend co_anchor_B282039653953_41}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Plaintiffs argue that Roxane\rquote s proposed products induce infringement of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 because Roxane\rquote s proposed product labels instruct users to perform each element of the claimed patented method. (D.I. 184 at 1.) According to the Plaintiffs, Roxane\rquote s Proposed Label recommends that prescribers perform each step of the claimed methods, including 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ib3510dc6475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
genotyping
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 their patients and administering up to 12 mg/day of iloperidone to genotypic CYP2D6 poor metabolizers. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
)
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Roxane responds that the dosage reduction on the label is merely educational language and that its label does not encourage a physician to perform or dose a patient based on a CYP2D6 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ib3510dc6475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
genotyping
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 test. (D.I. 185 at 3.) Roxane relies on the testimony of Dr. Kaye. Dr. Kaye testified that there is no mandate for genetic testing and that the language \u8220\'3fshould have their dose reduced by half\u8221\'3f is not a recommendation or suggestion to reduce the dosage in CYP2D6 PMs. Tr. at 462:1-464:11 (Kaye). The court did not find the testimony of Dr. Kaye to be credible. Roxane\rquote s other expert, Dr. Ratain, and the Plaintiffs\rquote s expert, Dr. Preskorn, testified that these words have their plain meaning and are a recommendation to reduce the dosage in this patient population. Tr. at 539:15\u8211\'3f25, 548:12\u8211\'3f16 (Ratain); 231:14\u8211\'3f19 (Preskorn). The court rejects Roxane\rquote s argument that this information is merely informative.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Roxane contends that while the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 claims require 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ib3510dc6475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
genotyping
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 testing, the label does not specify that the tests to determine poor metabolizers must be 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ib3510dc6475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
genotyping 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_434_41}{\*\bkmkend co_pp_sp_7903_434_41}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*434
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 tests. (D.I. 185 at 3.) Poor metabolizers can also be identified by laboratory tests that determine a patient\rquote s phenotype, such as measuring iloperidone concentrations. Tr. at 144:13-146:5 (Polymeropoulos); 211:14-215:7 (Kricka); 285:14-289:8 (Preskorn); 409:13-410:17, 411:17-413:16, 419:10-12 (Kaye); DTX-19 at 2; DTX-20 at 4; DTX-356; DTX-501; DTX-502; JX-36 at 7. According to Roxane, the label itself describes metabolizer status by reference to serum levels of iloperidone\u8212\'3fa measure of phenotype\u8212\'3fnot by reference to any allele or genetic variant. Tr. at 407:13-408:1 (Kaye); JX-11 at 21. Dr. Kaye explained that he had never genotyped a patient in connection with prescribing iloperidone. Tr. at 381:21-382:4 (Kaye). He further explained that a physician would not genotype a patient in order to determine what dose of a drug to use, because \u8220\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ib3510dc6475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
genotyping
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 does not predict efficacy or dose response.\u8221\'3f Tr. at 390:17-392:7 (Kaye). According to Dr. Kaye, phenotyping is more clinically helpful than CYP2D6 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ib3510dc6475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
genotyping
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Tr. at 412:11-413:16 (Kaye). In addition, Roxane posits that its label mandates titration to efficacy to determine the appropriate dosage. (D.I. 179, \u182\'3f 13.) Dr. Kaye testified that in accordance with the label\rquote s titration requirement, physicians always titrate to efficacy rather than rely on 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ib3510dc6475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
genotyping
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Tr. at 394:9-398:3, 400:6-403:20 (Kaye).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf23 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B292039653953_41}{\*\bkmkend co_anchor_B292039653953_41}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The evidence presented at trial suggests that as a practical matter, doctors may not rely on genotyping tests because of the resources and time they require. However, to determine whether there is induced infringement, the court is tasked with interpreting whether the label \u8220\'3fencourage [s], recommend[s], or promote[s] infringement.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036222044&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_631&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_631" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Takeda Pharm. U.S.A., Inc. v. West\u8211\'3fWard Pharm. Corp.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 785 F.3d 625, 631 (Fed.Cir.2015)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Roxane argues that because some prescribers of iloperidone will not follow the steps of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 by not genotyping their patients, there are substantial noninfringing uses and Roxane does not induce infringement. The court rejects this argument. \u8220\'3fThe pertinent question is whether the proposed label instructs users to perform the patented method. 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
If so, the proposed label may provide evidence of [Roxane]\rquote s affirmative intent to induce infringement.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2023571452&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1060&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1060" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
AstraZeneca LP v. Apotex Corp.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 633 F.3d 1042, 1060 (Fed.Cir.2010)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Moreover, the existence of a substantial non-infringing use does not preclude a finding of inducement. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2023998787&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1284&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1284" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Erbe Elektromedizin GmbH v. Canady Tech. LLC
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 629 F.3d 1278, 1284 (Fed.Cir.2010)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027871054&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1364&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1364" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Toshiba Corp. v. Imation Corp.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 681 F.3d 1358, 1364 (Fed.Cir.2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (holding that the district court\rquote s conclusion that a finding of a substantial non-infringing use precludes a finding of induced infringement was legal error). The court concludes that Roxane\rquote s label induces infringement of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ifea2ac711a0311ebb27dc1895c097}{\*\bkmkend co_anchor_Ifea2ac711a0311ebb27dc1895c097}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
4. 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa200 \sb400 
Contributory Infringement
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf23 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B302039653953_41}{\*\bkmkend co_anchor_B302039653953_41}
}
{\b0 \cf23 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B312039653953_41}{\*\bkmkend co_anchor_B312039653953_41}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In contrast, the Plaintiffs have not established contributory infringement. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_4b24000003ba5" }{\fldrslt 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat32 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(c)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Here, the Federal Circuit\rquote s opinion in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027871054&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Toshiba Corp. v. Imation Corp.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is instructive on the distinction between contributory and induced infringement. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027871054&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
681 F.3d 1358
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. An accused infringer may escape liability for contributory infringement if his product is capable of substantial non-infringing use. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027871054&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1362&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1362" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1362
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. On the other hand, if the accused infringer encourages infringing use, the fact that his product is capable of substantial non-infringing use will not save him from inducement liability. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027871054&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1365&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1365" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1365\u8211\'3f66
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Plaintiffs contend that Roxane\rquote s proposed products contribute to infringement because their proposed labels would contribute to direct infringement of the asserted claim and Roxane\rquote s products have no substantial noninfringing uses. The court cannot agree. The evidence presented at trial demonstrates that a physician could prescribe iloperidone without practicing 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_435_41}{\*\bkmkend co_pp_sp_7903_435_41}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*435
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 by not using a genotyping test. Tr. at 257:4-258:6 (Preskorn), 407:13-406:11 (Kaye), 503:22-504:3 (Ratain); JX-11 at 21. The burden is on the Plaintiffs to prove that there is not a substantial noninfringing use and the Plaintiffs have not met this burden. In this case, the testimony at trial established that the noninfringing uses are not \u8220\'3funusual, far-fetched, illusory, impractical, occasional, aberrant, or experimental.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019816886&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1327&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1327" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Vita\u8211\'3fMix Corp.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 581 F.3d at 1327
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In conclusion, Roxane\rquote s generic iloperidone as described in the Roxane ANDA would, if marketed, induce infringement of claims 1-9, 11-13, and 16 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. However, there are one or more substantially non-infringing uses for Roxane\rquote s generic iloperidone that preclude a finding of contributory infringement. Thus, Roxane does not contribute to the infringement of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ifea78e711a0311ebb27dc1895c097}{\*\bkmkend co_anchor_Ifea78e711a0311ebb27dc1895c097}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ifea78e711a0311ebb27dc1895c097}{\*\bkmkend co_anchor_Ifea78e711a0311ebb27dc1895c097}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
E. Remedies
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf23 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B322039653953_41}{\*\bkmkend co_anchor_B322039653953_41}
}
{\b0 \cf23 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B332039653953_41}{\*\bkmkend co_anchor_B332039653953_41}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Pursuant to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_e61400004a261" }{\fldrslt 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat32 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(e)(4)(B)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the court finds that Roxane, its officers, agents, attorneys, and employees, and those acting in privity or concert with any of them, should be enjoined from engaging in the commercial manufacture, use, offer to sell, or sale with the United States, or importation into the United States of Roxane\rquote s ANDA Product prior to the expiration of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2009579817&pubNum=0004073&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Id04ab71917f711db9a6ba61a2ffc7828&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 198 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_e61400004a261" }{\fldrslt 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat32 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(e)(4)(B)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The court finds that the Plaintiffs are not entitled to relief pursuant to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_f4aa000038542" }{\fldrslt 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat32 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(e)(4)(A)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 for the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 because the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 did not issue until after the effective date of any FDA approval of the Roxane ANDA of Roxane\rquote s ANDA No. 20-5480. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_f4aa000038542" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Section 271 (e)(4)(A)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 explicitly protects a patent that has already issued at the time of the ANDA\rquote s submission. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038776161&pubNum=0000999&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Endo Pharm. Inc. v. Amneal Pharm., LLC
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, No. 12 CIV. 8060 (TPG), 2016 WL 1732751, at *4 (S.D.N.Y. Apr. 29, 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_1184000067914" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 271(e)(2)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, it is an act of infringement to submit an ANDA under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=21USCAS355&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_267600008f864" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 355(j)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 for \u8220\'3f \u8216\'3fa drug claimed in a patent or the use of which is claimed in a patent.\u8217\'3f Notably, the subject of the sentence is \u8216\'3fa patent,\u8217\'3f not a provisional patent application or a patent-pending.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038776161&pubNum=0000780&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_780_3&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_3" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at *3
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf23 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B342039653953_41}{\*\bkmkend co_anchor_B342039653953_41}
}
{\b0 \cf23 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B352039653953_41}{\*\bkmkend co_anchor_B352039653953_41}
}
{\b0 \cf23 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B362039653953_41}{\*\bkmkend co_anchor_B362039653953_41}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
While the Plaintiffs are ineligible for the relief set forth in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_22700000861f0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 271(e)(4)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the court has the general equitable power to issue an injunction based upon the finding of patent infringement under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_8b3b0000958a4" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 271(a)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8211\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RE&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_4b24000003ba5" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(c)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, e.g.,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2009155959&pubNum=0000708&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
eBay Inc. v. MercExchange, LLC
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 547 U.S. 388, 126 S.Ct. 1837, 164 L.Ed.2d 641 (2006)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Before the court can enjoin Roxane, the Plaintiffs must demonstrate that such relief would be fair and equitable pursuant to the Supreme Court\rquote s analysis in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2009155959&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
eBay
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. A patent owner prevailing on the merits in a patent infringement suit is not automatically entitled to an injunction. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2009155959&pubNum=0000780&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_780_390&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_390" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
eBay
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 547 U.S. at 390, 126 S.Ct. 1837
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Rather, courts apply traditional equitable principles to determine: (1) whether the patentee would be irreparably harmed without an injunction; (2) whether the patentee has an adequate remedy at law; (3) whether the balance of hardships favors an injunction; and (4) whether granting the injunction is in the public interest. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2009155959&pubNum=0000708&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 391, 126 S.Ct. 1837
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The court will apply these considerations to the facts of this case.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf23 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B372039653953_41}{\*\bkmkend co_anchor_B372039653953_41}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Here, it is clear that Vanda would be irreparably harmed without an injunction. \u8220\'3fWhere a plaintiff and an infringer directly compete in the same market, an injunction may be warranted to protect the plaintiff from irreparable harm.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038776161&pubNum=0000999&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Endo Pharm. Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 2016 WL 1732751, at *5
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030572081&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1345&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1345" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Douglas Dynamics, LLC v. Buyers Prods. Co.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 717 F.3d 1336, 1345 (Fed.Cir.2013)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). Allowing generic products such as Roxane\rquote s into the market will no doubt cause harm to Vanda. Without an injunction, Plaintiffs would suffer an incalculable loss of market share and Roxane\rquote s generic iloperidone would erode the price for Fanapt\u174\'3f. 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_436_41}{\*\bkmkend co_pp_sp_7903_436_41}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*436
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Vanda would also suffer irreparable harm from being unable to use lost Fanapt\u174\'3f revenue to invest in research and development of new clinical indications for and formulations of Fanapt\u174\'3f and development of other drugs. These irreparable harms would be the direct result of Roxane\rquote s sales. (D.I. 178 at 26.) There is no other adequate remedy because these harms are and would continue to be difficult to quantify. On the other hand, Roxane has not demonstrated it would suffer hardship. Therefore, the balance of hardships weighs in favor of enjoining Roxane. Finally, the court finds that the public interest would not be disserved by a permanent injunction. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2009155959&pubNum=0000780&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_780_391&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_391" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
eBay
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 547 U.S. at 391, 126 S.Ct. 1837
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Vanda holds a valid patent and the Federal Circuit has \u8220\'3flong acknowledged the importance of the patent system in encouraging innovation. Indeed, the \u8216\'3fencouragement of investment-based risk is the fundamental purpose of the patent grant, and is based directly on the right to exclude.\u8217\'3f \u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2010878011&pubNum=0000506&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1383&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1383" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Sanofi\u8211\'3fSynthelabo v. Apotex, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 470 F.3d 1368, 1383 (Fed.Cir.2006)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1985112038&pubNum=0000350&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_350_599&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_599" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Patlex Corp. v. Mossinghoff
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 758 F.2d 594, 599 (Fed.Cir.1985)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In conclusion, the four 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2009155959&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
eBay
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 factors weigh in favor of issuing an injunction. The Plaintiffs are entitled to a permanent injunction restraining and enjoining Roxane, their officers, agents, servants, employees, attorneys, affiliates, divisions, subsidiaries, and those persons in active concert or participation with any of them from infringing the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 or inducing anyone to do the same, including the manufacture, use, offer to sell, sale, distribution, or importation of any generic iloperidone product described in the Roxane ANDA, or any amendments or supplements thereto until the expiration of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 on November 2, 2027.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ifeb12b611a0311ebb27dc1895c097}{\*\bkmkend co_anchor_Ifeb12b611a0311ebb27dc1895c097}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ifeb12b611a0311ebb27dc1895c097}{\*\bkmkend co_anchor_Ifeb12b611a0311ebb27dc1895c097}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
IV. CONCLUSION
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In sum, the court finds that (1) all asserted claims of the patents-in-suit are valid; (2) Roxane\rquote s proposed products induce infringement of the asserted claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; (3) Roxane\rquote s proposed products do not contributorily infringe the asserted claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; and (4) each of the parties\rquote  
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR52&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Rule 52(c)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 motions are granted in part and denied in part.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf31 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_allCitations_41}{\*\bkmkend co_allCitations_41}
{\b1 \cf31 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
All Citations
\par 
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
203 F.Supp.3d 412
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 \par}\sect\sbknone\pgncont\cols1{\ids0 {
{\trowd \ltrrow \trleft0 
\clpadl200 \clpadfl3 \clbrdrt \clbrdrl \trql \clwWidth10080 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs20 \li0 
{\b0 \cf1 \f3 \i0 \fs20 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Footnotes
\par 
}
}
}
}\b0 \cf1 \f3 \ri0 \ul0 \strike0 \i0 \ql \li0 \fs20 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f3 \i0 \fs24 
{\*\bkmkstart co_footnote_B00012039653953_41}{\*\bkmkend co_footnote_B00012039653953_41}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00012039653953_ID0EGGBI_41" }{\fldrslt 
{\super \b0 \cf23 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
1
}\super \b0 \cf23 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f3 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Roxane concedes infringement of claim 3 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2009579817&pubNum=0004073&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Id04ab71917f711db9a6ba61a2ffc7828&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\rquote 198 Patent
}\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, provided that the claim is not proved invalid. (D.I. 129.)
\par 
}
}
}
}
}\b0 \cf1 \f3 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f3 \i0 \fs24 
{\*\bkmkstart co_footnote_B00022039653953_41}{\*\bkmkend co_footnote_B00022039653953_41}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00022039653953_ID0ESHBI_41" }{\fldrslt 
{\super \b0 \cf23 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
2
}\super \b0 \cf23 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f3 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Prior to trial, the parties submitted an exhibit of uncontested facts in conjunction with their Pretrial Order. (D.I. 154, Ex. 1.) The court takes most of its findings of fact from the parties\rquote  uncontested facts. The court has also reordered and renumbered some paragraphs, corrected some formatting errors, and made minor edits for the purpose of concision and clarity that it does not believe alters the meaning of the paragraphs from the Pretrial Order. Otherwise, any differences between this section and the parties\rquote  statement of uncontested facts are unintentional.
\par 
}
}
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
The court\rquote s findings of fact with respect to matters that were the subject of dispute between the parties are included in Part III of this opinion (\u8220\'3fDiscussion and Conclusions of Law\u8221\'3f), preceded by the phrase \u8220\'3fthe court finds\u8221\'3f or \u8220\'3fthe court concludes.\u8221\'3f
\par 
}
}
}
}
}
}\b0 \cf1 \f3 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f3 \i0 \fs24 
{\*\bkmkstart co_footnote_B00032039653953_41}{\*\bkmkend co_footnote_B00032039653953_41}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00032039653953_ID0EJ5CI_41" }{\fldrslt 
{\super \b0 \cf23 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
3
}\super \b0 \cf23 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f3 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8220\'3fClear and convincing evidence is evidence that places in the fact finder \lquote an abiding conviction that the truth of [the] factual contentions are \u8216\'3fhighly probable.\u8217\'3f \u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2018512462&pubNum=0004637&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_4637_631&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_4637_631" }{\fldrslt 
{\b0 \cf23 \f3 \i1 \fs18 
{\b0 \cf23 \f3 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Alza Corp v. Andrx Pharms., LLC
}
}
{\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, 607 F.Supp.2d 614, 631 (D.Del.2009)
}\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1984126796&pubNum=0000780&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_780_316&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_316" }{\fldrslt 
{\b0 \cf23 \f3 \i1 \fs18 
{\b0 \cf23 \f3 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Colorado v. New Mexico
}
}
{\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, 467 U.S. 310, 316, 104 S.Ct. 2433, 81 L.Ed.2d 247 (1984)
}\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
).
\par 
}
}
}
}
}\b0 \cf1 \f3 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f3 \i0 \fs24 
{\*\bkmkstart co_footnote_B00042039653953_41}{\*\bkmkend co_footnote_B00042039653953_41}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00042039653953_ID0EQIDI_41" }{\fldrslt 
{\super \b0 \cf23 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
4
}\super \b0 \cf23 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f3 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \i1 \fs18 
{\b0 \cf1 \f3 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 Tr. at 676:7\u8211\'3f15 (Sargent); 820:5\u8211\'3f13 (Bartlett).
\par 
}
}
}
}
}\b0 \cf1 \f3 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \lastrow \trleft0 
\clbrdrb \clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrb \clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f3 \i0 \fs24 
{\*\bkmkstart co_footnote_B00052039653953_41}{\*\bkmkend co_footnote_B00052039653953_41}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00052039653953_ID0EDKDI_41" }{\fldrslt 
{\super \b0 \cf23 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
5
}\super \b0 \cf23 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f3 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
The parties disagree about the level of skill of ordinary skill in the art. Roxane contends that a skilled artisan would understand pharmacogenetics because the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\rquote 610 Patent
}\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 is about pharmacogenetics, Tr. at 512:6\u8211\'3f12 (Ratain); the Plaintiffs contend that the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I1391f6006c3811e69e6ceb9009bbadab&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\rquote 610 Patent
}\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 is about methods of treating 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ad584c475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
schizophrenia
}\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 patients using iloperidone, and thus a skilled artisan would need to be qualified to administer antipsychotics to patients but would not need a pharmacogenetics background. The difference is insignificant, however. Roxane\rquote s expert admits his opinion would not change under either articulation. Tr. at 515:20\u8211\'3f23 (Ratain). (
}
{\b0 \cf1 \f3 \i1 \fs18 
{\b0 \cf1 \f3 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 D.I. 178 at 17.)
\par 
}
}
}
}
}\b0 \cf1 \f3 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }}\par 
}
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 \par}\sect\sbknone\pgncont\cols1{\ids0 {
{\trowd \lastrow \trleft0 
\clpadt24 \clpadft3 \clpadl100 \clpadfl3 \clpadr24 \clpadfr3 \clbrdrt \brdrcf25 \brdrw10 \brdrs \clbrdrb \clbrdrl \trql \clvertalt \clwWidth4320 \cellx4320 
\clpadt29 \clpadft3 \clpadl100 \clpadfl3 \clpadr29 \clpadfr3 \clbrdrt \brdrcf25 \brdrw10 \brdrs \clbrdrb \clbrdrr \trql \clvertalt \clwWidth5760 \cellx10080 
\intbl 
{\ri24 \li24 
{\b1 \cf25 \f3 \ri24 \i0 \ql \fs16 \li24 
{\b1 \cf25 \f3 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
End of Document
\par 
}
}
}\b1 \cf25 \f3 \ri24 \ul0 \strike0 \i0 \ql \li24 \fs16 \sa0 \sb0 \intbl \cell \intbl 
{\ri29 \li29 
{\qr \b0 \cf25 \f3 \ri29 \i0 \fs19 \li29 
{\b0 \cf25 \f3 \ul0 \strike0 \i0 \fs19 \sa0 \sb0 
\u169\'3f 2021 Thomson Reuters. No claim to original U.S. Government Works.
\par 
}
}
}\qr \b0 \cf25 \f3 \ri29 \ul0 \strike0 \i0 \li29 \fs19 \sa0 \sb0 \intbl \cell \row }}\par 
}
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}\sect }